CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | alditol |
|
Accession: | CHEBI:17522
|
browse the term
|
Definition: | A carbohydrate that is an acyclic polyol having the general formula HOCH2[CH(OH)]nCH2OH (formally derivable from an aldose by reduction of the carbonyl group). |
Synonyms: | related_synonym: | Formula=(CH2O)nC2H6O2; Glycitol; Sugar alcohol; alditols |
| alt_id: | CHEBI:13754; CHEBI:22298; CHEBI:2556 |
| xref: | KEGG:C00717; Wikipedia:Glycerin |
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
decreases expression |
ISO |
trilinolenin results in decreased expression of ABCA1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
decreases expression |
ISO |
trilinolenin results in decreased expression of ABCG5 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
decreases expression |
ISO |
trilinolenin results in decreased expression of ABCG8 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression |
ISO |
trilinolenin results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases expression |
ISO |
trilinolenin results in increased expression of HMGCR mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
increases expression |
ISO |
trilinolenin results in increased expression of MTTP mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Npc1l1 |
NPC1 like intracellular cholesterol transporter 1 |
decreases expression |
ISO |
trilinolenin results in decreased expression of NPC1L1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113
|
|
G |
Scd |
stearoyl-CoA desaturase |
decreases expression |
ISO |
trilinolenin results in decreased expression of SCD1 mRNA |
CTD |
PMID:8729090 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
decreases expression |
ISO |
trilinolein results in decreased expression of ABCA1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
decreases expression |
ISO |
trilinolein results in decreased expression of ABCG5 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
decreases expression |
ISO |
trilinolein results in decreased expression of ABCG8 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression |
ISO |
trilinolein results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases expression |
ISO |
trilinolein results in increased expression of HMGCR mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
increases expression |
ISO |
trilinolein results in increased expression of MTTP mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Npc1l1 |
NPC1 like intracellular cholesterol transporter 1 |
decreases expression |
ISO |
trilinolein results in decreased expression of NPC1L1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions decreases expression |
ISO |
Clofibrate inhibits the reaction [trilinolein results in decreased expression of SCD1 mRNA] |
CTD |
PMID:8790349 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
[dibutyrylglycerol analog co-treated with Fluorescein-5-isothiocyanate] affects the secretion of IL4 protein |
CTD |
PMID:29198882 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Trpa1 |
transient receptor potential cation channel, subfamily A, member 1 |
increases activity |
ISO |
dibutyrylglycerol analog results in increased activity of TRPA1 protein |
CTD |
PMID:29198882 |
|
NCBI chr 5:4,379,862...4,434,133
Ensembl chr 5:4,379,999...4,433,570
|
|
|
G |
Pnlip |
pancreatic lipase |
increases metabolic processing |
ISO |
PNLIP protein results in increased metabolism of 1,2-didecanoylglycerol |
CTD |
PMID:9822688 |
|
NCBI chr 1:257,774,012...257,811,656
Ensembl chr 1:257,798,581...257,811,654
|
|
G |
Pnliprp2 |
pancreatic lipase related protein 2 |
increases metabolic processing |
EXP |
PNLIPRP2 protein results in increased metabolism of 1,2-didecanoylglycerol |
CTD |
PMID:9822688 |
|
NCBI chr 1:257,897,766...257,916,434
Ensembl chr 1:257,897,766...257,916,434
|
|
G |
Sprr1a |
small proline-rich protein 1A |
increases expression |
ISO |
1,2-didecanoylglycerol results in increased expression of SPRR1A protein |
CTD |
PMID:8617999 |
|
NCBI chr 2:178,055,096...178,057,012
Ensembl chr 2:178,055,096...178,057,063
|
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
1,2-Dipalmitoylphosphatidylcholine inhibits the reaction [Asbestos, Crocidolite results in increased secretion of IL6 protein] |
CTD |
PMID:19041333 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Prnp |
prion protein |
multiple interactions affects folding |
ISO |
Copper affects the reaction [1,2-Dipalmitoylphosphatidylcholine affects the folding of PRNP protein modified form] |
CTD |
PMID:20936829 |
|
NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937
|
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
dioctanoylphosphatidic acid results in increased expression of PTGS2 protein |
CTD |
PMID:11854442 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
|
G |
Fech |
ferrochelatase |
affects abundance |
ISO |
FECH protein affects the abundance of 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine |
CTD |
PMID:29906468 |
|
NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348
|
|
|
G |
Fech |
ferrochelatase |
affects abundance |
ISO |
FECH protein affects the abundance of 1-palmitoyl-2-linoleoylphosphatidylcholine |
CTD |
PMID:29906468 |
|
NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348
|
|
|
G |
Iyd |
iodotyrosine deiodinase |
multiple interactions |
ISO |
1-monomyristin inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine] |
CTD |
PMID:33352258 |
|
NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319
|
|
|
G |
Nr5a2 |
nuclear receptor subfamily 5, group A, member 2 |
multiple interactions |
ISO |
[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of 1-oleoyl lysophosphatidylcholine |
CTD |
PMID:29515023 |
|
NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326
|
|
G |
Smad3 |
SMAD family member 3 |
decreases abundance |
ISO |
SMAD3 protein results in decreased abundance of 1-oleoyl lysophosphatidylcholine |
CTD |
PMID:23034213 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of AGTR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of ALOX5 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CCR2 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Cd68 |
Cd68 molecule |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CD68 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Crp |
C-reactive protein |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CRP mRNA |
CTD |
PMID:16386258 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions increases phosphorylation |
EXP |
AG 1879 inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of GJA1 protein]; resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of GJA1 protein] |
CTD |
PMID:24079413 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of IL1A mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of IL1B mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Kcnab2 |
potassium voltage-gated channel subfamily A regulatory beta subunit 2 |
multiple interactions |
EXP |
[KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine |
CTD |
PMID:21296056 |
|
NCBI chr 5:162,899,511...162,988,057
Ensembl chr 5:162,901,896...162,988,243
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
EXP |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK1 protein resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:24079413 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP |
resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:24079413 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of OLR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Ptafr |
platelet-activating factor receptor |
affects binding multiple interactions |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine binds to PTAFR protein 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine inhibits the reaction [Platelet Activating Factor binds to PTAFR protein] |
CTD |
PMID:16386258 |
|
NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of PTGS1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of PTGS2 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Sele |
selectin E |
increases expression increases secretion |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of SELE mRNA 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased secretion of SELE protein |
CTD |
PMID:16386258 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions increases phosphorylation |
EXP |
resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of SRC protein] |
CTD |
PMID:24079413 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Timp4 |
TIMP metallopeptidase inhibitor 4 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of TIMP4 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 4:148,306,021...148,312,558
Ensembl chr 4:148,304,490...148,312,558
|
|
G |
Tnf |
tumor necrosis factor |
increases expression increases secretion |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of TNF mRNA 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased secretion of TNF protein |
CTD |
PMID:16386258 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of ACTA2 mRNA N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of ACTA2 mRNA] |
CTD |
PMID:24706986 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein]; Resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein] 1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:14769825 PMID:17550345 PMID:20103642 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
ISO |
ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]; Masoprocol inhibits the reaction [ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]] |
CTD |
PMID:10698703 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions |
ISO |
[Lithocholic Acid co-treated with lysophosphatidic acid] results in increased activity of ALPL protein |
CTD |
PMID:19646460 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Bcar1 |
BCAR1 scaffold protein, Cas family member |
increases phosphorylation |
ISO |
lysophosphatidic acid results in increased phosphorylation of BCAR1 protein |
CTD |
PMID:11792571 |
|
NCBI chr19:39,679,215...39,713,907
Ensembl chr19:39,679,204...39,713,907
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression |
ISO |
lysophosphatidic acid analog results in increased expression of BCL2 protein; lysophosphatidic acid results in increased expression of BCL2 protein |
CTD |
PMID:23251428 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
C5 |
complement C5 |
increases expression |
ISO |
lysophosphatidic acid results in increased expression of HC protein |
CTD |
PMID:25822713 |
|
NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
lysophosphatidic acid analog inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein]; lysophosphatidic acid inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein] |
CTD |
PMID:23251428 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccl12 |
C-C motif chemokine ligand 12 |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of CCL12 protein 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CCL12 protein] |
CTD |
PMID:25822713 |
|
NCBI chr10:67,070,230...67,071,780
Ensembl chr10:67,070,230...67,071,780
|
|
G |
Ccl28 |
C-C motif chemokine ligand 28 |
multiple interactions increases expression |
ISO |
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CCL28 protein] |
CTD |
PMID:25822713 |
|
NCBI chr 2:51,601,354...51,625,999
Ensembl chr 2:51,601,331...51,625,997
|
|
G |
Ccn1 |
cellular communication network factor 1 |
multiple interactions increases expression |
ISO |
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CCN1 protein] |
CTD |
PMID:25822713 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression multiple interactions |
EXP ISO |
lysophosphatidic acid results in increased expression of CCN2 protein N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 mRNA] Simvastatin inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein]; Y 27632 inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein] |
CTD |
PMID:15200425 PMID:24706986 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of COL1A2 mRNA N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of COL1A2 mRNA] |
CTD |
PMID:24706986 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Csf1 |
colony stimulating factor 1 |
increases expression |
ISO |
lysophosphatidic acid results in increased expression of CSF1 protein |
CTD |
PMID:25822713 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of CXCL12 protein 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CXCL12 protein] |
CTD |
PMID:25822713 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl16 |
C-X-C motif chemokine ligand 16 |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of CXCL16 protein 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CXCL16 protein] |
CTD |
PMID:25822713 |
|
NCBI chr10:55,166,721...55,171,316
Ensembl chr10:55,166,723...55,171,592
|
|
G |
Cxcr1 |
C-X-C motif chemokine receptor 1 |
multiple interactions decreases expression |
ISO |
lysophosphatidic acid inhibits the reaction [CXCR1 protein binds to LPAR1 protein]; lysophosphatidic acid results in decreased expression of [CXCR1 protein binds to LPAR1 protein] lysophosphatidic acid results in decreased expression of CXCR1 mRNA |
CTD |
PMID:16224106 |
|
NCBI chr 9:75,766,894...75,771,079
Ensembl chr 9:75,766,770...75,771,084
|
|
G |
Dgka |
diacylglycerol kinase, alpha |
multiple interactions |
ISO |
DGKA protein promotes the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein] |
CTD |
PMID:10913605 |
|
NCBI chr 7:1,148,734...1,175,324
Ensembl chr 7:1,148,735...1,175,110
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions increases phosphorylation |
ISO |
GNA13 mutant form inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein] |
CTD |
PMID:23127547 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions increases phosphorylation |
EXP |
1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; 2-butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:14769825 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
multiple interactions decreases expression |
ISO EXP |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; 3-(2-methoxybenzylamino)-2-phenylpiperidine inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; [[Capsaicin results in increased chemical synthesis of Lysophosphatidylcholines] which results in increased secretion of Lysophosphatidylcholines] promotes the reaction [ENPP2 results in increased chemical synthesis of lysophosphatidic acid]; [[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid] which results in decreased expression of NFE2L2; [[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased chemical synthesis of and results in decreased abundance of lysophosphatidic acid] which results in increased expression of ENPP2 mRNA; [ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid; [ENPP2 protein co-treated with Lysophosphatidylcholines] results in increased chemical synthesis of lysophosphatidic acid; [ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid; [ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased chemical synthesis of and results in decreased abundance of lysophosphatidic acid; arachidonyltrifluoromethane inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; bisindolylmaleimide I inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; Dizocilpine Maleate inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; IL1B protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein]; TNF protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein]; U 0126 inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; xestospongin C inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid] lysophosphatidic acid inhibits the reaction [ENPP2 mutant form results in decreased expression of MBP mRNA] |
CTD |
PMID:18594965 PMID:19014389 PMID:24599971 PMID:24747415 PMID:25398768 PMID:25896349 More...
|
|
NCBI chr 7:86,202,345...86,325,050
Ensembl chr 7:86,202,350...86,324,827
|
|
G |
Epo |
erythropoietin |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GYPA mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein] |
CTD |
PMID:21915944 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Gata1 |
GATA binding protein 1 |
multiple interactions |
ISO |
[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA] |
CTD |
PMID:21915944 |
|
NCBI chr X:14,529,706...14,537,530
Ensembl chr X:14,529,702...14,537,530
|
|
G |
Gna13 |
G protein subunit alpha 13 |
multiple interactions |
ISO |
GNA13 mutant form inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein] |
CTD |
PMID:23127547 |
|
NCBI chr10:94,337,939...94,370,774
Ensembl chr10:94,337,725...94,370,774
|
|
G |
Gypa |
glycophorin A |
multiple interactions |
ISO |
lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GYPA mRNA] |
CTD |
PMID:21915944 |
|
NCBI chr19:27,450,304...27,465,940
Ensembl chr19:27,450,308...27,465,822
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions increases expression |
ISO |
L-4F peptide inhibits the reaction [lysophosphatidic acid results in increased expression of HIF1A protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of HIF1A protein] [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA mRNA; [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA protein; lysophosphatidic acid results in increased expression of HIF1A protein |
CTD |
PMID:17919812 PMID:22537771 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
multiple interactions increases phosphorylation |
EXP |
MK2i peptide inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of HSPB1 protein]; SB 203580 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of HSPB1 protein] |
CTD |
PMID:20864298 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
IL1B protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein] |
CTD |
PMID:25896349 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases secretion |
ISO |
lysophosphatidic acid results in increased secretion of IL6 protein |
CTD |
PMID:21821728 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il6st |
interleukin 6 cytokine family signal transducer |
multiple interactions increases expression |
ISO |
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of IL6ST protein] |
CTD |
PMID:25822713 |
|
NCBI chr 2:44,065,979...44,106,255
Ensembl chr 2:44,066,130...44,109,936
|
|
G |
Kitlg |
KIT ligand |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GYPA mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein] |
CTD |
PMID:21915944 |
|
NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214
|
|
G |
Kng1 |
kininogen 1 |
multiple interactions |
EXP |
KNG1 protein inhibits the reaction [[Wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein] |
CTD |
PMID:10537051 |
|
NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555
|
|
G |
Lama3 |
laminin subunit alpha 3 |
increases expression |
ISO |
lysophosphatidic acid results in increased expression of LAMA3 mRNA |
CTD |
PMID:15541073 |
|
NCBI chr18:3,523,168...3,751,722
Ensembl chr18:3,523,133...3,751,353
|
|
G |
Lamb3 |
laminin subunit beta 3 |
increases expression |
ISO |
lysophosphatidic acid results in increased expression of LAMB3 mRNA |
CTD |
PMID:15541073 |
|
NCBI chr13:104,833,810...104,875,405
Ensembl chr13:104,833,873...104,875,405
|
|
G |
Lamc2 |
laminin subunit gamma 2 |
increases expression |
ISO |
lysophosphatidic acid results in increased expression of LAMC2 mRNA |
CTD |
PMID:15541073 |
|
NCBI chr13:65,284,664...65,344,164
Ensembl chr13:65,284,664...65,344,200
|
|
G |
Lpar1 |
lysophosphatidic acid receptor 1 |
increases response to substance multiple interactions |
ISO |
LPAR1 protein results in increased susceptibility to lysophosphatidic acid LPAR1 protein affects the reaction [lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein]; lysophosphatidic acid inhibits the reaction [CXCR1 protein binds to LPAR1 protein]; lysophosphatidic acid results in decreased expression of [CXCR1 protein binds to LPAR1 protein] |
CTD |
PMID:16224106 PMID:16809448 PMID:25398768 |
|
NCBI chr 5:73,229,047...73,347,874
Ensembl chr 5:73,229,625...73,369,895
|
|
G |
Lpar3 |
lysophosphatidic acid receptor 3 |
multiple interactions |
ISO |
Endocannabinoids inhibits the reaction [lysophosphatidic acid binds to and results in increased activity of LPAR3 protein]; lysophosphatidic acid binds to and results in increased activity of LPAR3 protein |
CTD |
PMID:30102254 |
|
NCBI chr 2:235,125,234...235,193,916
Ensembl chr 2:235,149,065...235,193,357
|
|
G |
Lpar5 |
lysophosphatidic acid receptor 5 |
multiple interactions |
ISO |
Endocannabinoids inhibits the reaction [lysophosphatidic acid binds to and results in increased activity of LPAR5 protein]; lysophosphatidic acid binds to and results in increased activity of LPAR5 protein |
CTD |
PMID:30102254 |
|
NCBI chr 4:157,870,493...157,883,979
Ensembl chr 4:157,881,796...157,882,950
|
|
G |
Lpar6 |
lysophosphatidic acid receptor 6 |
multiple interactions |
ISO |
lysophosphatidic acid binds to and results in increased activity of LPAR6 protein |
CTD |
PMID:18297070 |
|
NCBI chr15:48,416,548...48,418,357
Ensembl chr15:48,416,544...48,422,331
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
Hydrogen Peroxide promotes the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein] 1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:11243883 PMID:12657697 PMID:15081308 PMID:17919812 PMID:21179406 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
Hydrogen Peroxide promotes the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein] 1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11243883 PMID:12657697 PMID:15081308 PMID:17919812 PMID:21179406 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mbp |
myelin basic protein |
multiple interactions |
EXP |
lysophosphatidic acid inhibits the reaction [ENPP2 mutant form results in decreased expression of MBP mRNA] |
CTD |
PMID:18594965 |
|
NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression |
ISO |
gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]] |
CTD |
PMID:23127547 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
increases phosphorylation |
EXP |
lysophosphatidic acid results in increased phosphorylation of MTOR protein |
CTD |
PMID:14769825 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Myl9 |
myosin light chain 9 |
increases phosphorylation multiple interactions |
ISO |
lysophosphatidic acid results in increased phosphorylation of MYL9 protein Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MYL9 protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MYL9 protein] |
CTD |
PMID:24587105 |
|
NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333
|
|
G |
Mylk |
myosin light chain kinase |
affects response to substance |
ISO |
MYLK protein affects the susceptibility to lysophosphatidic acid |
CTD |
PMID:10640419 |
|
NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
LPAR1 protein affects the reaction [lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein]; lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein [[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid] which results in decreased expression of NFE2L2 |
CTD |
PMID:25398768 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions increases expression |
EXP |
Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased expression of NPPA protein]; Y 27632 inhibits the reaction [lysophosphatidic acid results in increased expression of NPPA protein] |
CTD |
PMID:15081308 PMID:25449040 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Pip5k1a |
phosphatidylinositol-4-phosphate 5-kinase, type 1, alpha |
multiple interactions increases activity |
ISO |
1-Butanol inhibits the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein]; DGKA protein promotes the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein] |
CTD |
PMID:10913605 |
|
NCBI chr 2:182,628,299...182,671,584
Ensembl chr 2:182,628,300...182,671,598
|
|
G |
Plau |
plasminogen activator, urokinase |
multiple interactions increases expression |
ISO |
gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]] |
CTD |
PMID:23127547 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Pld1 |
phospholipase D1 |
multiple interactions increases activity |
EXP |
1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]]; 1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]]; bisindolylmaleimide I inhibits the reaction [lysophosphatidic acid results in increased activity of PLD1 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased activity of PLD1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; toxB protein, Clostridium difficile inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of PLD1 protein] |
CTD |
PMID:11243883 PMID:14769825 |
|
NCBI chr 2:110,849,205...111,047,304
Ensembl chr 2:110,893,608...111,047,692
|
|
G |
Ppp1r12a |
protein phosphatase 1, regulatory subunit 12A |
increases phosphorylation multiple interactions |
EXP |
lysophosphatidic acid results in increased phosphorylation of PPP1R12A protein Y 27632 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of PPP1R12A protein] |
CTD |
PMID:25449040 |
|
NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
increases phosphorylation multiple interactions |
ISO EXP |
lysophosphatidic acid results in increased phosphorylation of PTK2 protein [wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein; KNG1 protein inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein] [wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein; Atropine inhibits the reaction [oxotremorine M inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein]]; oxotremorine M inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein] |
CTD |
PMID:10537051 PMID:11792571 |
|
NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
|
|
G |
Ptk2b |
protein tyrosine kinase 2 beta |
increases phosphorylation |
ISO |
lysophosphatidic acid results in increased phosphorylation of PTK2B protein |
CTD |
PMID:11792571 |
|
NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282
|
|
G |
Rhoa |
ras homolog family member A |
increases activity multiple interactions |
EXP ISO |
lysophosphatidic acid results in increased activity of RHOA protein Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOA protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOA protein] |
CTD |
PMID:15081308 PMID:24587105 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rhoc |
ras homolog family member C |
multiple interactions increases activity |
ISO |
Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOC protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOC protein] |
CTD |
PMID:24587105 |
|
NCBI chr 2:192,287,065...192,293,292
Ensembl chr 2:192,287,130...192,295,306
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
increases phosphorylation multiple interactions |
ISO EXP |
lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein] 1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:14769825 PMID:17919812 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein] |
CTD |
PMID:21915944 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions increases expression |
ISO |
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of TIMP1 protein] |
CTD |
PMID:25822713 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
TNF protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein] |
CTD |
PMID:25896349 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression multiple interactions |
ISO |
[lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA mRNA; [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA protein resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of VEGFA protein] |
CTD |
PMID:17919812 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions decreases abundance |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol LIPC gene mutant form results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol |
CTD |
PMID:24777581 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lipg |
lipase G, endothelial type |
decreases abundance multiple interactions |
ISO |
LIPG gene mutant form results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol [LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol |
CTD |
PMID:24777581 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
1-oleoyl-2-acetylglycerol inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; 1-oleoyl-2-acetylglycerol results in increased phosphorylation of and results in decreased expression of ABCA1 protein |
CTD |
PMID:16118212 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions |
ISO |
1-oleoyl-2-acetylglycerol inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]] |
CTD |
PMID:16118212 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
multiple interactions |
ISO |
1-oleoyl-2-acetylglycerol promotes the reaction [[Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium] |
CTD |
PMID:18316702 |
|
NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356
|
|
G |
Fgg |
fibrinogen gamma chain |
increases expression |
ISO |
1-oleoyl-2-acetylglycerol results in increased expression of FGG mRNA |
CTD |
PMID:2440878 |
|
NCBI chr 2:168,354,880...168,362,325
Ensembl chr 2:168,355,013...168,362,322
|
|
G |
Ins2 |
insulin 2 |
affects response to substance |
ISO |
INS protein affects the susceptibility to 1-oleoyl-2-acetylglycerol |
CTD |
PMID:22031853 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Pthlh |
parathyroid hormone-like hormone |
increases secretion |
EXP |
1-oleoyl-2-acetylglycerol results in increased secretion of PTHLH protein |
CTD |
PMID:7946399 |
|
NCBI chr 4:180,188,792...180,199,847
Ensembl chr 4:180,188,792...180,199,847
|
|
G |
Trpa1 |
transient receptor potential cation channel, subfamily A, member 1 |
increases activity multiple interactions |
ISO |
1-oleoyl-2-acetylglycerol results in increased activity of TRPA1 protein Ruthenium Red inhibits the reaction [1-oleoyl-2-acetylglycerol results in increased activity of TRPA1 protein] |
CTD |
PMID:15046718 |
|
NCBI chr 5:4,379,862...4,434,133
Ensembl chr 5:4,379,999...4,433,570
|
|
G |
Trpc3 |
transient receptor potential cation channel, subfamily C, member 3 |
increases activity multiple interactions |
ISO |
1-oleoyl-2-acetylglycerol results in increased activity of TRPC3 protein ethyl-1-(4-(2*3*3-trichloroacrylamide)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate inhibits the reaction [1-oleoyl-2-acetylglycerol results in increased activity of TRPC3 protein] 1-oleoyl-2-acetylglycerol affects the reaction [TRPC3 protein affects the transport of Calcium]; 1-oleoyl-2-acetylglycerol promotes the reaction [TRPC3 protein results in increased transport of Barium]; 1-oleoyl-2-acetylglycerol promotes the reaction [TRPC3 protein results in increased transport of Calcium] |
CTD |
PMID:11042129 PMID:12700192 PMID:16522635 PMID:17351372 PMID:18316702 PMID:19289841 More...
|
|
NCBI chr 2:119,481,313...119,619,333
Ensembl chr 2:119,481,400...119,558,855
|
|
G |
Trpc4 |
transient receptor potential cation channel, subfamily C, member 4 |
multiple interactions |
ISO |
TRPC4 protein affects the reaction [1-oleoyl-2-acetylglycerol results in increased transport of Strontium] |
CTD |
PMID:11830588 |
|
NCBI chr 2:138,307,676...138,476,856
Ensembl chr 2:138,308,084...138,476,768
|
|
G |
Trpc5 |
transient receptor potential cation channel, subfamily C, member 5 |
multiple interactions |
ISO |
1-oleoyl-2-acetylglycerol affects the reaction [TRPC5 protein affects the transport of Calcium] |
CTD |
PMID:17351372 |
|
NCBI chr X:107,946,163...108,230,991
Ensembl chr X:107,939,131...108,230,991
|
|
G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
increases activity multiple interactions affects response to substance |
ISO EXP |
1-oleoyl-2-acetylglycerol results in increased activity of TRPC6 protein 4-((3,4-(methylenedioxy)benzyl)amino)-6-methoxyquinazoline analog inhibits the reaction [1-oleoyl-2-acetylglycerol results in increased activity of TRPC6 protein]; 8-bromocyclic GMP inhibits the reaction [1-oleoyl-2-acetylglycerol results in increased activity of TRPC6 protein]; KT 5823 inhibits the reaction [4-((3,4-(methylenedioxy)benzyl)amino)-6-methoxyquinazoline analog inhibits the reaction [1-oleoyl-2-acetylglycerol results in increased activity of TRPC6 protein]]; S-Nitroso-N-Acetylpenicillamine inhibits the reaction [1-oleoyl-2-acetylglycerol results in increased activity of TRPC6 protein] 1-oleoyl-2-acetylglycerol results in increased activity of TRPC6 protein; 1-oleoyl-2-acetylglycerol results in increased activity of TRPC6 protein mutant form TRPC6 protein affects the susceptibility to 1-oleoyl-2-acetylglycerol |
CTD |
PMID:18316702 PMID:20177073 PMID:22031853 |
|
NCBI chr 8:5,759,387...5,864,000
Ensembl chr 8:5,758,935...5,828,092
|
|
G |
Trpm6 |
transient receptor potential cation channel, subfamily M, member 6 |
multiple interactions |
ISO |
Gadolinium inhibits the reaction [TRPM6 protein affects the reaction [1-oleoyl-2-acetylglycerol results in increased transport of Calcium]]; Lanthanum inhibits the reaction [TRPM6 protein affects the reaction [1-oleoyl-2-acetylglycerol results in increased transport of Calcium]]; TRPM6 protein affects the reaction [1-oleoyl-2-acetylglycerol results in increased transport of Barium]; TRPM6 protein affects the reaction [1-oleoyl-2-acetylglycerol results in increased transport of Calcium]; TRPM6 protein affects the reaction [1-oleoyl-2-acetylglycerol results in increased transport of Strontium] |
CTD |
PMID:11988098 |
|
NCBI chr 1:216,136,407...216,320,523
Ensembl chr 1:216,170,038...216,320,520
|
|
|
G |
Lipg |
lipase G, endothelial type |
increases hydrolysis |
ISO |
LIPG protein results in increased hydrolysis of 1-O-hexadecyl-2-arachidonyl-sn-glycero-3-phosphocholine |
CTD |
PMID:15953354 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Lipc |
lipase C, hepatic type |
decreases abundance |
ISO |
LIPC gene mutant form results in decreased abundance of 1-palmitoyl-2-oleoyl-sn-glycerol |
CTD |
PMID:24777581 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lipg |
lipase G, endothelial type |
decreases abundance |
ISO |
LIPG gene mutant form results in decreased abundance of 1-palmitoyl-2-oleoyl-sn-glycerol |
CTD |
PMID:24777581 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
1-stearoyl-2-arachidonoylglycerol inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:27936102 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Dagla |
diacylglycerol lipase, alpha |
increases metabolic processing |
ISO |
DAGLA protein results in increased metabolism of 1-stearoyl-2-arachidonoylglycerol |
CTD |
PMID:18657971 |
|
NCBI chr 1:206,890,635...206,947,332
Ensembl chr 1:206,890,638...206,947,232
|
|
G |
Daglb |
diacylglycerol lipase, beta |
increases metabolic processing |
ISO |
DAGLB protein results in increased metabolism of 1-stearoyl-2-arachidonoylglycerol |
CTD |
PMID:18657971 |
|
NCBI chr12:11,059,732...11,102,170
Ensembl chr12:11,059,732...11,102,154
|
|
G |
Dgke |
diacylglycerol kinase epsilon |
increases phosphorylation |
ISO |
DGKE protein results in increased phosphorylation of 1-stearoyl-2-arachidonoylglycerol |
CTD |
PMID:17455907 |
|
NCBI chr10:73,853,030...73,877,334
Ensembl chr10:73,855,583...73,877,100
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
ISO |
1-stearoyl-2-arachidonoylglycerol results in increased expression of PPARGC1A mRNA |
CTD |
PMID:23056435 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
1-stearoyl-2-arachidonoylglycerol inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:27936102 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Trpm6 |
transient receptor potential cation channel, subfamily M, member 6 |
multiple interactions |
ISO |
TRPM6 protein affects the reaction [1-stearoyl-2-arachidonoylglycerol results in increased transport of Barium]; TRPM6 protein affects the reaction [1-stearoyl-2-arachidonoylglycerol results in increased transport of Calcium] |
CTD |
PMID:11988098 |
|
NCBI chr 1:216,136,407...216,320,523
Ensembl chr 1:216,170,038...216,320,520
|
|
|
G |
Lipc |
lipase C, hepatic type |
decreases abundance |
ISO |
LIPC gene mutant form results in decreased abundance of 1-stearoyl-2-linoleoyl-sn-glycerol |
CTD |
PMID:24777581 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lipg |
lipase G, endothelial type |
decreases abundance |
ISO |
LIPG gene mutant form results in decreased abundance of 1-stearoyl-2-linoleoyl-sn-glycerol |
CTD |
PMID:24777581 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of stearoyl alpha-lysolecithin |
CTD |
PMID:24777581 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lipg |
lipase G, endothelial type |
multiple interactions |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of stearoyl alpha-lysolecithin |
CTD |
PMID:24777581 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of AGTR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Alox12 |
arachidonate 12-lipoxygenase, 12S type |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of ALOX12 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions increases expression |
ISO |
[sodium arsenite co-treated with Platelet Activating Factor co-treated with Arachidonic Acid] results in increased phosphorylation of and results in increased activity of ALOX5 protein; [zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [Calcimycin results in increased abundance of Platelet Activating Factor] Platelet Activating Factor results in increased expression of ALOX5 mRNA |
CTD |
PMID:8387780 PMID:10779545 PMID:16386258 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases secretion |
ISO |
Foropafant inhibits the reaction [Platelet Activating Factor results in increased secretion of CCL2 protein] |
CTD |
PMID:15149885 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of CCR2 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Crp |
C-reactive protein |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of CRP mRNA |
CTD |
PMID:16386258 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of CX3CR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 8:119,785,726...119,799,431
Ensembl chr 8:119,782,595...119,800,014
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions increases abundance |
EXP |
Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]; EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]; EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor] |
CTD |
PMID:18205269 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ednrb |
endothelin receptor type B |
multiple interactions |
EXP |
EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]; EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor] |
CTD |
PMID:18205269 |
|
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of EGR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
EXP |
[Platelet Activating Factor co-treated with Cytochalasin B] results in increased secretion of GUSB protein; IMMLG5521 inhibits the reaction [[Platelet Activating Factor co-treated with Cytochalasin B] results in increased secretion of GUSB protein] |
CTD |
PMID:23850278 |
|
NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of IL1A mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression increases secretion multiple interactions |
ISO |
Platelet Activating Factor results in increased expression of IL1B mRNA Platelet Activating Factor results in increased secretion of IL1B protein [Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL1B protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL1B protein] |
CTD |
PMID:16386258 PMID:32830409 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases secretion |
ISO |
[Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL6 protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL6 protein] |
CTD |
PMID:32830409 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions increases expression |
ISO |
Foropafant inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]; Isoproterenol promotes the reaction [Theophylline inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]]; Theophylline inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein] |
CTD |
PMID:9762784 PMID:11116075 |
|
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Ltb4r |
leukotriene B4 receptor |
affects response to substance |
ISO |
LTB4R1 protein affects the susceptibility to Platelet Activating Factor |
CTD |
PMID:10934231 |
|
NCBI chr15:29,263,199...29,265,716
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of MMP13 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
increases expression multiple interactions |
ISO |
Platelet Activating Factor results in increased expression of MYD88 protein PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased expression of MYD88 protein] |
CTD |
PMID:32830409 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nceh1 |
neutral cholesterol ester hydrolase 1 |
multiple interactions |
ISO |
NCEH1 protein inhibits the reaction [[Chlorpyrifos metabolite co-treated with Cytidine Diphosphate Choline] results in increased abundance of Platelet Activating Factor] |
CTD |
PMID:18164358 |
|
NCBI chr 2:110,074,985...110,135,592
Ensembl chr 2:110,074,957...110,135,588
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions increases degradation |
ISO |
Acetylcysteine inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; BN 50739 inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Genistein inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; herbimycin inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Vitamin E inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein] |
CTD |
PMID:10921504 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of OLR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Pla2g7 |
phospholipase A2 group VII |
multiple interactions increases expression |
ISO |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Platelet Activating Factor] results in increased expression of PLA2G7 mRNA; bepafant inhibits the reaction [Platelet Activating Factor results in increased expression of PLA2G7 mRNA] |
CTD |
PMID:21432021 |
|
NCBI chr 9:17,362,214...17,404,476
Ensembl chr 9:17,362,225...17,404,476
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases expression |
ISO |
Platelet Activating Factor results in decreased expression of PPARA mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ptafr |
platelet-activating factor receptor |
multiple interactions increases expression increases phosphorylation affects binding |
ISO EXP |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; BN 50730 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; BN 50739 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; CMI 392 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; MK 287 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; zileuton inhibits the reaction [Platelet Activating Factor binds to PTAFR protein] Platelet Activating Factor results in increased expression of PTAFR mRNA Platelet Activating Factor results in increased phosphorylation of PTAFR protein bepafant inhibits the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA]; Carbon Tetrachloride promotes the reaction [Platelet Activating Factor binds to PTAFR protein]; RGS4 protein inhibits the reaction [Platelet Activating Factor results in increased phosphorylation of PTAFR protein]; TNF protein affects the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA] |
CTD |
PMID:9065783 PMID:10447766 PMID:11297424 PMID:11529688 PMID:16386258 PMID:18205269 More...
|
|
NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of PTGS1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of PTGS2 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pvt1 |
Pvt1 oncogene |
increases expression multiple interactions |
ISO |
Platelet Activating Factor results in increased expression of PVT1 mRNA [Platelet Activating Factor co-treated with PVT1 mRNA] affects the expression of MIR149 mRNA; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased expression of MYD88 protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL1B protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL6 protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of TNF protein] |
CTD |
PMID:32830409 |
|
NCBI chr 7:93,656,528...93,879,938
|
|
G |
Rgs4 |
regulator of G-protein signaling 4 |
multiple interactions |
EXP |
RGS4 protein inhibits the reaction [Platelet Activating Factor results in increased phosphorylation of PTAFR protein] |
CTD |
PMID:11297424 |
|
NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068
|
|
G |
Sele |
selectin E |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of SELE mRNA |
CTD |
PMID:16386258 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Sell |
selectin L |
multiple interactions increases secretion |
ISO |
Isoproterenol promotes the reaction [Theophylline inhibits the reaction [Platelet Activating Factor results in increased secretion of SELL protein]]; Theophylline inhibits the reaction [Platelet Activating Factor results in increased secretion of SELL protein] |
CTD |
PMID:9762784 |
|
NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456
|
|
G |
Selp |
selectin P |
multiple interactions increases expression |
ISO |
Foropafant inhibits the reaction [Platelet Activating Factor results in increased expression of SELP protein] |
CTD |
PMID:11116075 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Timp4 |
TIMP metallopeptidase inhibitor 4 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of TIMP4 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 4:148,306,021...148,312,558
Ensembl chr 4:148,304,490...148,312,558
|
|
G |
Tnf |
tumor necrosis factor |
increases secretion multiple interactions increases expression |
ISO EXP |
Platelet Activating Factor results in increased secretion of TNF protein [Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of TNF protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of TNF protein] TNF protein affects the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA] Platelet Activating Factor results in increased expression of TNF mRNA Acetylcysteine inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; BN 50739 inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; Vitamin E inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA] |
CTD |
PMID:9065783 PMID:10921504 PMID:16386258 PMID:32830409 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Abhd12 |
abhydrolase domain containing 12, lysophospholipase |
increases hydrolysis |
ISO |
ABHD12 protein results in increased hydrolysis of glyceryl 2-arachidonate |
CTD |
PMID:18096503 |
|
NCBI chr 3:139,659,315...139,719,529
Ensembl chr 3:139,659,317...139,719,564
|
|
G |
Abhd6 |
abhydrolase domain containing 6, acylglycerol lipase |
increases hydrolysis |
ISO |
ABHD6 protein results in increased hydrolysis of glyceryl 2-arachidonate |
CTD |
PMID:18096503 |
|
NCBI chr15:16,859,740...16,907,094
Ensembl chr15:16,859,738...16,906,985
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression multiple interactions |
EXP |
glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA] |
CTD |
PMID:21863215 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
ISO |
[[APOE protein affects the susceptibility to [Cholesterol, Dietary co-treated with Dietary Fats]] which affects the susceptibility to JZL 184] which affects the abundance of glyceryl 2-arachidonate |
CTD |
PMID:29813086 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Arrb1 |
arrestin, beta 1 |
multiple interactions |
ISO |
glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] |
CTD |
PMID:31024316 |
|
NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein] |
CTD |
PMID:31024316 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of ATF4 mRNA iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of ATF4 mRNA] |
CTD |
PMID:32357311 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of BTG2 mRNA |
CTD |
PMID:28095641 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of CCL2 protein |
CTD |
PMID:15115777 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccr1 |
C-C motif chemokine receptor 1 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of CCR1 mRNA |
CTD |
PMID:29813086 |
|
NCBI chr 8:123,556,286...123,561,841
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of CD36 mRNA |
CTD |
PMID:29813086 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Ces1d |
carboxylesterase 1D |
increases hydrolysis multiple interactions |
ISO |
CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate [CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid |
CTD |
PMID:21049984 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ces2h |
carboxylesterase 2H |
increases hydrolysis multiple interactions |
ISO |
CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate [CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid |
CTD |
PMID:21049984 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions increases expression |
ISO EXP |
[CNR1 protein affects the susceptibility to Chlorpyrifos] which affects the hydrolysis of glyceryl 2-arachidonate; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]] glyceryl 2-arachidonate results in increased expression of CNR1 mRNA [GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of CNR1 mRNA]; Nitroglycerin affects the reaction [glyceryl 2-arachidonate affects the activity of CNR1 protein] |
CTD |
PMID:12657697 PMID:15899896 PMID:16775503 PMID:21863215 PMID:23894352 PMID:26209559 PMID:28095641 PMID:31024316 PMID:36858108 More...
|
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions affects response to substance |
ISO |
[GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; [SR 144528 binds to and results in increased activity of CNR2 protein] inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]; glyceryl 2-arachidonate binds to and results in increased activity of CNR2 protein; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; Pertussis Toxin inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]]; SR 144528 inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]] CNR2 gene SNP affects the susceptibility to glyceryl 2-arachidonate |
CTD |
PMID:10617657 PMID:15115777 PMID:20124950 PMID:27194477 PMID:30102254 PMID:31024316 More...
|
|
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Creb3l3 |
cAMP responsive element binding protein 3-like 3 |
multiple interactions increases expression |
ISO |
glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA] |
CTD |
PMID:23894352 |
|
NCBI chr 7:8,622,614...8,631,053
Ensembl chr 7:8,622,614...8,631,048
|
|
G |
Crh |
corticotropin releasing hormone |
increases abundance |
ISO |
CRH protein results in increased abundance of glyceryl 2-arachidonate |
CTD |
PMID:26821211 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA] |
CTD |
PMID:23894352 PMID:28095641 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions increases expression |
ISO |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA] |
CTD |
PMID:23894352 PMID:28095641 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA] |
CTD |
PMID:23894352 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA] |
CTD |
PMID:23894352 PMID:28095641 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Dagla |
diacylglycerol lipase, alpha |
multiple interactions |
ISO |
1-((fluoro(methyl)phosphoryl)oxy)-3-isopropoxypropan-2-yl oleate inhibits the reaction [DAGLA protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate] |
CTD |
PMID:27071101 |
|
NCBI chr 1:206,890,635...206,947,332
Ensembl chr 1:206,890,638...206,947,232
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA; glyceryl 2-arachidonate results in increased expression of DDIT3 protein iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 protein] |
CTD |
PMID:29441458 PMID:32357311 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions increases phosphorylation |
ISO |
GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:32357311 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Esrrg |
estrogen-related receptor gamma |
increases abundance |
ISO |
ESRRG protein results in increased abundance of glyceryl 2-arachidonate |
CTD |
PMID:31912162 |
|
NCBI chr13:99,167,656...99,788,016
Ensembl chr13:99,564,669...99,783,397
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
affects abundance multiple interactions |
ISO |
FABP1 protein affects the abundance of glyceryl 2-arachidonate FABP1 protein affects the reaction [Dronabinol results in increased abundance of glyceryl 2-arachidonate]; FABP1 protein affects the reaction [glyceryl 2-arachidonate results in increased abundance of anandamide] |
CTD |
PMID:29414765 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fmr1 |
fragile X messenger ribonucleoprotein 1 |
multiple interactions |
ISO |
[FMR1 gene mutant form results in increased activity of MGLL] which results in increased degradation of glyceryl 2-arachidonate |
CTD |
PMID:20393458 |
|
NCBI chr X:147,240,239...147,278,057
Ensembl chr X:147,240,301...147,278,050
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
multiple interactions |
EXP |
FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12657697 |
|
NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
|
|
G |
Grk2 |
G protein-coupled receptor kinase 2 |
multiple interactions |
ISO |
[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] |
CTD |
PMID:31024316 |
|
NCBI chr 1:201,580,823...201,601,580
Ensembl chr 1:201,581,480...201,601,582
|
|
G |
Hcrt |
hypocretin neuropeptide precursor |
increases chemical synthesis multiple interactions |
ISO |
HCRT protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea inhibits the reaction [HCRT protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate] |
CTD |
PMID:27071101 |
|
NCBI chr10:85,689,979...85,691,214
Ensembl chr10:85,689,465...85,691,210
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of HSPA5 mRNA |
CTD |
PMID:32357311 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of ICAM1 mRNA |
CTD |
PMID:29813086 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in decreased expression of IL1B mRNA glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]] |
CTD |
PMID:16364651 PMID:30611738 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]; T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]] |
CTD |
PMID:21511917 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il6 |
interleukin 6 |
decreases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in decreased expression of IL6 mRNA glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]] |
CTD |
PMID:16364651 PMID:30611738 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
glyceryl 2-arachidonate promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]; N-(3-methoxyphenyl)-4-chlorocinnamanilide inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]] |
CTD |
PMID:31408376 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA] |
CTD |
PMID:23894352 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
[Dietary Fats co-treated with LEP protein] results in increased chemical synthesis of glyceryl 2-arachidonate |
CTD |
PMID:27071101 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation |
ISO EXP |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:12657697 PMID:31917333 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation |
ISO EXP |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12657697 PMID:31917333 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mgll |
monoglyceride lipase |
multiple interactions affects abundance increases degradation increases abundance increases hydrolysis |
EXP ISO |
[Chlorpyrifos results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate; JZL 184 inhibits the reaction [MGLL protein results in increased hydrolysis of glyceryl 2-arachidonate] MGLL protein affects the abundance of glyceryl 2-arachidonate MGLL protein results in increased degradation of glyceryl 2-arachidonate [FMR1 gene mutant form results in increased activity of MGLL] which results in increased degradation of glyceryl 2-arachidonate; [JZL 184 results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate; [MJN110 results in decreased activity of MGLL protein] which results in decreased hydrolysis of and results in increased abundance of glyceryl 2-arachidonate MGLL gene mutant form results in increased abundance of glyceryl 2-arachidonate |
CTD |
PMID:18096503 PMID:20393458 PMID:21507991 PMID:23761300 PMID:25030704 PMID:26209559 PMID:26642910 PMID:26791602 PMID:30301768 More...
|
|
NCBI chr 4:121,192,186...121,294,187
Ensembl chr 4:121,192,195...121,294,179
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased activity of MPO protein]] |
CTD |
PMID:30611738 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased cleavage of PARP1 protein] |
CTD |
PMID:29441458 PMID:32357311 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
affects localization multiple interactions |
EXP |
glyceryl 2-arachidonate affects the localization of PPARA protein [palmidrol co-treated with glyceryl 2-arachidonate] affects the localization of PPARA protein; [palmidrol co-treated with glyceryl 2-arachidonate] affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein]; glyceryl 2-arachidonate affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein] |
CTD |
PMID:31787870 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects binding multiple interactions increases expression |
ISO |
glyceryl 2-arachidonate metabolite binds to PPARG protein glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in decreased expression of PPARG protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]] T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite results in increased expression of PPARG mRNA] |
CTD |
PMID:21511917 PMID:26209559 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
EXP |
[Indomethacin results in decreased expression of PTGS1] which results in increased activity of glyceryl 2-arachidonate |
CTD |
PMID:17245358 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases metabolic processing multiple interactions |
ISO |
PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate 2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; rimonabant inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]] glyceryl 2-arachidonate inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased expression of PTGS2 mRNA]; Ibuprofen inhibits the reaction [PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate] |
CTD |
PMID:18297109 PMID:21511917 PMID:26209559 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]] |
CTD |
PMID:26209559 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO EXP |
glyceryl 2-arachidonate results in decreased expression of TNF mRNA glyceryl 2-arachidonate inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein]; glyceryl 2-arachidonate inhibits the reaction [amyloid beta-protein (25-35) results in increased expression of TNF protein] glyceryl 2-arachidonate inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] |
CTD |
PMID:12509806 PMID:16364651 PMID:30611738 PMID:30769029 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions affects response to substance |
EXP ISO |
glyceryl 2-arachidonate binds to and results in increased activity of TRPV1 protein TRPV1 protein affects the susceptibility to glyceryl 2-arachidonate |
CTD |
PMID:18550765 PMID:21949157 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Yy1 |
YY1 transcription factor |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of YY1 mRNA |
CTD |
PMID:28095641 |
|
NCBI chr 6:127,706,739...127,736,499
Ensembl chr 6:127,707,596...127,732,747
|
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
EXP |
platelet-activating factor increases expression of Tnf protein in portal stenosis rat plasma |
RGD |
PMID:10452877 |
RGD:38508900 |
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
affects abundance |
ISO |
FABP1 protein affects the abundance of 2-oleoylglycerol |
CTD |
PMID:29414765 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Mgll |
monoglyceride lipase |
increases degradation multiple interactions |
EXP |
MGLL protein results in increased degradation of 2-oleoylglycerol Nitroglycerin promotes the reaction [MGLL protein results in increased degradation of 2-oleoylglycerol] |
CTD |
PMID:19515121 |
|
NCBI chr 4:121,192,186...121,294,187
Ensembl chr 4:121,192,195...121,294,179
|
|
|
G |
Pafah1b1 |
platelet-activating factor acetylhydrolase 1b, regulatory subunit 1 |
increases expression multiple interactions |
EXP |
Castor Oil results in increased expression of PAFAH1B1 protein isosorbide-5-mononitrate inhibits the reaction [Castor Oil results in increased expression of PAFAH1B1 protein] |
CTD |
PMID:1354728 PMID:2743081 PMID:8738301 |
|
NCBI chr10:59,533,042...59,591,808
Ensembl chr10:59,534,117...59,591,808
|
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
multiple interactions increases abundance |
ISO |
AKR1B1 protein promotes the reaction [Glucose results in increased abundance of Sorbitol] AKR1B1 protein results in increased abundance of Sorbitol |
CTD |
PMID:25451566 PMID:25541468 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
ISO |
[Sorbitol co-treated with Calcimycin co-treated with Arachidonic Acid] affects the localization of ALOX5 protein; SB 203580 inhibits the reaction [Sorbitol results in increased activity of ALOX5 protein]; Sorbitol results in increased phosphorylation of and results in increased activity of ALOX5 protein |
CTD |
PMID:10779545 PMID:11698504 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Aqp9 |
aquaporin 9 |
multiple interactions increases uptake |
ISO EXP |
Sorbitol inhibits the reaction [AQP9 protein results in increased uptake of arsenite] AQP9 protein results in increased uptake of Sorbitol |
CTD |
PMID:9733774 PMID:19341753 |
|
NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395
|
|
G |
Caprin1 |
cell cycle associated protein 1 |
multiple interactions |
ISO |
Sorbitol promotes the reaction [SNRNP200 protein binds to CAPRIN1 protein] |
CTD |
PMID:33939924 |
|
NCBI chr 3:90,152,305...90,230,447
Ensembl chr 3:90,153,620...90,230,502
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
EXP |
Sorbitol results in increased activity of CASP3 protein Spironolactone inhibits the reaction [Testosterone inhibits the reaction [Sorbitol results in increased activity of CASP3 protein]]; Testosterone inhibits the reaction [Sorbitol results in increased activity of CASP3 protein] |
CTD |
PMID:20609311 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases activity multiple interactions |
EXP |
Sorbitol results in increased activity of CASP8 protein Spironolactone inhibits the reaction [Testosterone inhibits the reaction [Sorbitol results in increased activity of CASP8 protein]]; Testosterone inhibits the reaction [Sorbitol results in increased activity of CASP8 protein] |
CTD |
PMID:20609311 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity multiple interactions |
EXP |
Sorbitol results in increased activity of CASP9 protein Spironolactone inhibits the reaction [Testosterone inhibits the reaction [Sorbitol results in increased activity of CASP9 protein]]; Testosterone inhibits the reaction [Sorbitol results in increased activity of CASP9 protein] |
CTD |
PMID:20609311 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Crk |
CRK proto-oncogene, adaptor protein |
increases phosphorylation |
EXP |
Sorbitol results in increased phosphorylation of CRK protein |
CTD |
PMID:16187300 |
|
NCBI chr10:60,530,469...60,556,703
Ensembl chr10:60,530,464...60,553,406
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
multiple interactions |
ISO |
Sorbitol promotes the reaction [EIF4E protein binds to EIF4EBP1 protein] |
CTD |
PMID:9545260 |
|
NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
Sorbitol promotes the reaction [EIF4E protein binds to EIF4EBP1 protein] |
CTD |
PMID:9545260 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Fmr1 |
fragile X messenger ribonucleoprotein 1 |
increases abundance |
ISO |
FMR1 5' UTR mutant form results in increased abundance of Sorbitol |
CTD |
PMID:27385396 |
|
NCBI chr X:147,240,239...147,278,057
Ensembl chr X:147,240,301...147,278,050
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
Sorbitol promotes the reaction [Glucose results in increased secretion of INS1 protein] |
CTD |
PMID:10221768 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases phosphorylation |
ISO |
JNK-IN-8 inhibits the reaction [Sorbitol results in increased phosphorylation of JUN protein] |
CTD |
PMID:24184208 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Mapk10 |
mitogen activated protein kinase 10 |
multiple interactions increases activity |
ISO |
Dicumarol inhibits the reaction [Sorbitol results in increased activity of MAPK10 protein] |
CTD |
PMID:10531305 |
|
NCBI chr14:6,497,662...6,790,109
Ensembl chr14:6,497,707...6,786,201
|
|
G |
Mapk12 |
mitogen-activated protein kinase 12 |
increases phosphorylation |
ISO |
Sorbitol results in increased phosphorylation of MAPK12 protein |
CTD |
PMID:15362974 |
|
NCBI chr 7:120,206,005...120,216,711
Ensembl chr 7:120,206,271...120,216,664
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
increases phosphorylation |
ISO |
Sorbitol results in increased phosphorylation of MAPK14 protein |
CTD |
PMID:15362974 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk7 |
mitogen-activated protein kinase 7 |
increases activity |
ISO |
Sorbitol results in increased activity of MAPK7 protein |
CTD |
PMID:11163183 |
|
NCBI chr10:46,170,264...46,176,262
Ensembl chr10:46,170,167...46,176,267
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation |
ISO |
Sorbitol results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:24184208 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
increases phosphorylation |
ISO |
Sorbitol results in increased phosphorylation of MAPK9 protein |
CTD |
PMID:24184208 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mapkapk2 |
MAPK activated protein kinase 2 |
increases activity increases phosphorylation multiple interactions |
ISO |
Sorbitol results in increased activity of MAPKAPK2 protein Sorbitol results in increased phosphorylation of MAPKAPK2 protein SB 203580 inhibits the reaction [Sorbitol results in increased phosphorylation of MAPKAPK2 protein] |
CTD |
PMID:9545260 PMID:15362974 |
|
NCBI chr13:42,513,762...42,560,061
Ensembl chr13:42,513,762...42,560,457
|
|
G |
Mknk1 |
MAPK interacting serine/threonine kinase 1 |
increases activity |
ISO |
Sorbitol results in increased activity of MKNK1 protein |
CTD |
PMID:9545260 |
|
NCBI chr 5:129,318,128...129,357,641
Ensembl chr 5:129,318,170...129,357,639
|
|
G |
Oat |
ornithine aminotransferase |
multiple interactions |
EXP |
Sorbitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein] |
CTD |
PMID:2827574 |
|
NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
|
|
G |
Pten |
phosphatase and tensin homolog |
affects localization |
ISO EXP |
Sorbitol affects the localization of PTEN protein |
CTD |
PMID:16807353 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Snrnp200 |
small nuclear ribonucleoprotein U5 subunit 200 |
multiple interactions |
ISO |
Sorbitol promotes the reaction [SNRNP200 protein binds to CAPRIN1 protein] |
CTD |
PMID:33939924 |
|
NCBI chr 3:114,428,854...114,458,194
Ensembl chr 3:114,428,854...114,458,182
|
|
G |
Sord |
sorbitol dehydrogenase |
multiple interactions increases abundance increases metabolic processing |
ISO |
[SORD protein results in increased metabolism of Sorbitol] which results in increased abundance of Fructose; epalrestat inhibits the reaction [SORD protein mutant form results in increased abundance of Sorbitol]; ranirestat inhibits the reaction [SORD protein mutant form results in increased abundance of Sorbitol] |
CTD |
PMID:32367058 |
|
NCBI chr 3:109,184,697...109,216,133
Ensembl chr 3:109,184,676...109,216,133
|
|
G |
Tardbp |
TAR DNA binding protein |
increases ubiquitination |
ISO |
Sorbitol results in increased ubiquitination of TARDBP protein |
CTD |
PMID:31780563 |
|
NCBI chr 5:159,050,518...159,062,218
Ensembl chr 5:159,051,799...159,062,055
|
|
G |
Ubxn1 |
UBX domain protein 1 |
increases phosphorylation |
ISO |
Sorbitol results in increased phosphorylation of UBXN1 protein |
CTD |
PMID:15362974 |
|
NCBI chr 1:205,765,309...205,769,234
Ensembl chr 1:205,745,120...205,816,520
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
EXP |
Mannitol inhibits the reaction [Vitamin A results in decreased expression of ABCB1 mRNA]; Mannitol inhibits the reaction [Vitamin A results in decreased expression of ABCB1A mRNA] |
CTD |
PMID:15327746 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Acacb |
acetyl-CoA carboxylase beta |
decreases expression |
ISO |
Mannitol results in decreased expression of ACACB mRNA |
CTD |
PMID:25270620 |
|
NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655
|
|
G |
Acly |
ATP citrate lyase |
increases expression |
ISO |
Mannitol results in increased expression of ACLY mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Adamts18 |
ADAM metallopeptidase with thrombospondin type 1 motif, 18 |
increases expression |
ISO |
Mannitol results in increased expression of ADAMTS18 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr19:41,686,951...41,840,035
Ensembl chr19:41,688,617...41,839,781
|
|
G |
Aida |
axin interactor, dorsalization associated |
decreases expression |
ISO |
Mannitol results in decreased expression of AIDA mRNA |
CTD |
PMID:25270620 |
|
NCBI chr13:94,940,311...94,967,920
Ensembl chr13:94,939,741...94,967,920
|
|
G |
Aire |
autoimmune regulator |
decreases expression |
ISO |
Mannitol results in decreased expression of AIRE mRNA |
CTD |
PMID:25270620 |
|
NCBI chr20:10,636,058...10,651,060
Ensembl chr20:10,636,123...10,651,060
|
|
G |
Aqp9 |
aquaporin 9 |
increases uptake |
EXP |
AQP9 protein results in increased uptake of Mannitol |
CTD |
PMID:9733774 |
|
NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395
|
|
G |
Arhgap1 |
Rho GTPase activating protein 1 |
increases expression |
ISO |
Mannitol results in increased expression of ARHGAP1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:77,621,377...77,643,400
Ensembl chr 3:77,620,655...77,643,396
|
|
G |
Arr3 |
arrestin 3 |
increases expression |
ISO |
Mannitol results in increased expression of ARR3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr X:65,699,881...65,712,224
Ensembl chr X:65,698,699...65,712,153
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases phosphorylation multiple interactions |
EXP |
Mannitol results in increased phosphorylation of BAD protein wortmannin inhibits the reaction [Mannitol results in increased phosphorylation of BAD protein] |
CTD |
PMID:15786717 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Mannitol inhibits the reaction [[cupric chloride co-treated with di(2-picolyl)amine-3(bromoacetyl)coumarin] results in increased expression of BAX protein] |
CTD |
PMID:29803612 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbox1 |
gamma-butyrobetaine hydroxylase 1 |
decreases expression |
ISO |
Mannitol results in decreased expression of BBOX1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:96,822,654...96,871,786
Ensembl chr 3:96,822,655...96,871,458
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression |
EXP |
Mannitol results in increased expression of BCL2 protein |
CTD |
PMID:15786717 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Cables2 |
Cdk5 and Abl enzyme substrate 2 |
decreases expression |
ISO |
Mannitol results in decreased expression of CABLES2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:167,347,527...167,362,274
Ensembl chr 3:167,347,461...167,362,279
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
IGF1 inhibits the reaction [Mannitol results in increased activity of CASP3 protein]; Mannitol inhibits the reaction [[cupric chloride co-treated with di(2-picolyl)amine-3(bromoacetyl)coumarin] results in increased activity of CASP3 protein] |
CTD |
PMID:10567913 PMID:12011046 PMID:29803612 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
Mannitol results in increased activity of CASP9 protein |
CTD |
PMID:12011046 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cbx1 |
chromobox 1 |
increases expression |
ISO |
Mannitol results in increased expression of CBX1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:81,770,307...81,789,981
Ensembl chr10:81,770,342...81,791,096
|
|
G |
Ccdc127 |
coiled-coil domain containing 127 |
decreases expression |
ISO |
Mannitol results in decreased expression of CCDC127 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:28,928,420...28,935,885
Ensembl chr 1:28,928,325...28,935,893
|
|
G |
Ccn3 |
cellular communication network factor 3 |
decreases expression |
ISO |
Mannitol results in decreased expression of CCN3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:86,094,000...86,101,022
Ensembl chr 7:86,094,000...86,101,019
|
|
G |
Ckap5 |
cytoskeleton associated protein 5 |
increases expression |
ISO |
Mannitol results in increased expression of CKAP5 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:77,491,195...77,593,300
Ensembl chr 3:77,491,276...77,593,264
|
|
G |
Clcn3 |
chloride voltage-gated channel 3 |
affects response to substance |
ISO |
CLCN3 protein affects the susceptibility to Mannitol deficiency |
CTD |
PMID:22108225 |
|
NCBI chr16:29,127,152...29,200,133
Ensembl chr16:29,127,419...29,200,119
|
|
G |
Ctnna2 |
catenin alpha 2 |
decreases expression |
ISO |
Mannitol results in decreased expression of CTNNA2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 4:109,294,249...110,443,409
Ensembl chr 4:109,293,978...110,443,522
|
|
G |
Dbh |
dopamine beta-hydroxylase |
increases expression |
ISO |
Mannitol results in increased expression of DBH mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:10,488,260...10,505,245
Ensembl chr 3:10,488,260...10,505,248
|
|
G |
Dctn2 |
dynactin subunit 2 |
increases expression |
ISO |
Mannitol results in increased expression of DCTN2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:63,092,061...63,107,560
Ensembl chr 7:63,092,057...63,108,543
|
|
G |
Dgka |
diacylglycerol kinase, alpha |
increases expression |
ISO |
Mannitol results in increased expression of DGKA mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:1,148,734...1,175,324
Ensembl chr 7:1,148,735...1,175,110
|
|
G |
Elf2 |
E74 like ETS transcription factor 2 |
increases expression |
ISO |
Mannitol results in increased expression of ELF2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:135,292,291...135,385,942
Ensembl chr 2:135,294,906...135,385,947
|
|
G |
Fam185a |
family with sequence similarity 185, member A |
increases expression |
ISO |
Mannitol results in increased expression of FAM185A mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 4:13,542,022...13,662,967
Ensembl chr 4:13,608,464...13,662,967
|
|
G |
Fam222a |
family with sequence similarity 222, member A |
decreases expression |
ISO |
Mannitol results in decreased expression of FAM222A mRNA |
CTD |
PMID:25270620 |
|
NCBI chr12:41,982,064...42,033,085
Ensembl chr12:41,986,780...42,033,682
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
Mannitol results in increased expression of FOS mRNA |
CTD |
PMID:11557636 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gal3st2 |
galactose-3-O-sulfotransferase 2 |
decreases expression |
ISO |
Mannitol results in decreased expression of GAL3ST2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 9:94,382,456...94,387,990
|
|
G |
Gas2l2 |
growth arrest-specific 2 like 2 |
decreases expression |
ISO |
Mannitol results in decreased expression of GAS2L2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:68,222,475...68,229,877
Ensembl chr10:68,222,475...68,229,881
|
|
G |
Gpc6 |
glypican 6 |
increases expression |
ISO |
Mannitol results in increased expression of GPC6 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr15:94,030,218...95,027,883
Ensembl chr15:94,029,884...95,024,006
|
|
G |
Gpr19 |
G protein-coupled receptor 19 |
decreases expression |
ISO |
Mannitol results in decreased expression of GPR19 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 4:167,710,944...167,739,232
Ensembl chr 4:167,710,666...167,741,036
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
Mannitol results in increased expression of HMOX1 mRNA |
CTD |
PMID:11592956 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hprt1 |
hypoxanthine phosphoribosyltransferase 1 |
increases expression |
ISO |
Mannitol results in increased expression of HPRT1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr X:132,736,175...132,768,149
Ensembl chr X:132,736,096...132,768,154
|
|
G |
Hrh2 |
histamine receptor H 2 |
increases expression |
ISO |
Mannitol results in increased expression of HRH2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr17:10,366,004...10,407,791
Ensembl chr17:10,368,298...10,407,631
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Mannitol inhibits the reaction [Glucose results in increased expression of ICAM1 mRNA]; Mannitol inhibits the reaction [Glucose results in increased expression of ICAM1 protein] |
CTD |
PMID:16285992 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
ISO |
IGF1 inhibits the reaction [Mannitol results in increased activity of CASP3 protein] |
CTD |
PMID:10567913 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Mannitol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Rotenone inhibits the reaction [Mannitol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]] |
CTD |
PMID:23867654 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
Mannitol results in increased expression of JUN mRNA |
CTD |
PMID:11557636 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Khdc3 |
KH domain containing 3, subcortical maternal complex member |
increases expression |
ISO |
Mannitol results in increased expression of KHDC3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:73,842,344...73,844,248
Ensembl chr 8:73,842,344...73,844,248
|
|
G |
Krtap11-1 |
keratin associated protein 11-1 |
increases expression |
ISO |
Mannitol results in increased expression of KRTAP11-1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr11:28,809,940...28,810,944
Ensembl chr11:28,810,341...28,810,892
|
|
G |
Lsm6 |
LSM6 homolog, U6 small nuclear RNA and mRNA degradation associated |
decreases expression |
ISO |
Mannitol results in decreased expression of LSM6 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr19:29,098,254...29,112,858
Ensembl chr13:42,114,032...42,116,484 Ensembl chr19:42,114,032...42,116,484
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
EXP |
Mannitol inhibits the reaction [Vitamin A results in increased phosphorylation of MAP2K1 protein] |
CTD |
PMID:16510265 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
multiple interactions |
EXP |
Mannitol inhibits the reaction [Vitamin A results in increased phosphorylation of MAP2K2 protein] |
CTD |
PMID:16510265 |
|
NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Mannitol promotes the reaction [potassium chromate(VI) results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:10910949 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
Mannitol promotes the reaction [potassium chromate(VI) results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:10910949 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mta2 |
metastasis associated 1 family, member 2 |
increases expression |
ISO |
Mannitol results in increased expression of MTA2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:205,838,181...205,846,903
Ensembl chr 1:205,837,964...205,846,946
|
|
G |
Myl9 |
myosin light chain 9 |
decreases phosphorylation |
EXP |
Mannitol results in decreased phosphorylation of MYL9 protein |
CTD |
PMID:17272349 |
|
NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333
|
|
G |
Mylk3 |
myosin light chain kinase 3 |
increases expression |
ISO |
Mannitol results in increased expression of MYLK3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr19:21,685,085...21,743,587
Ensembl chr19:21,691,929...21,742,954
|
|
G |
Naalad2 |
N-acetylated alpha-linked acidic dipeptidase 2 |
increases expression |
ISO |
Mannitol results in increased expression of NAALAD2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:15,406,119...15,479,714
Ensembl chr 8:15,407,043...15,479,714
|
|
G |
Ndufa13 |
NADH:ubiquinone oxidoreductase subunit A13 |
decreases expression |
ISO |
Mannitol results in decreased expression of NDUFA13 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr16:19,526,633...19,533,567
Ensembl chr16:19,526,565...19,535,726
|
|
G |
Nfat5 |
nuclear factor of activated T-cells 5 |
increases expression |
ISO |
Mannitol results in increased expression of NFAT5 mRNA |
CTD |
PMID:23867654 |
|
NCBI chr19:35,199,737...35,286,675
Ensembl chr19:35,199,016...35,286,675
|
|
G |
Nkg7 |
natural killer cell granule protein 7 |
increases expression |
ISO |
Mannitol results in increased expression of NKG7 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:93,844,748...93,845,975
Ensembl chr 1:93,844,902...93,845,983
|
|
G |
Nppa |
natriuretic peptide A |
increases expression |
ISO |
Mannitol results in increased expression of NPPA protein |
CTD |
PMID:2177369 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nts |
neurotensin |
increases transport |
EXP |
NTS protein results in increased transport of Mannitol |
CTD |
PMID:11208724 |
|
NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423
|
|
G |
Oat |
ornithine aminotransferase |
multiple interactions |
EXP |
Mannitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein] |
CTD |
PMID:2827574 |
|
NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
|
|
G |
Pcp2 |
Purkinje cell protein 2 |
increases expression |
ISO |
Mannitol results in increased expression of PCP2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr12:1,681,659...1,683,899
Ensembl chr12:1,681,659...1,683,899
|
|
G |
Pdcd4 |
programmed cell death 4 |
increases expression decreases expression |
ISO |
Mannitol results in increased expression of PDCD4 mRNA Mannitol results in decreased expression of PDCD4 mRNA |
CTD |
PMID:21873647 |
|
NCBI chr 1:252,921,342...252,944,278
Ensembl chr 1:252,921,392...252,944,275
|
|
G |
Plcl2 |
phospholipase C-like 2 |
decreases expression |
ISO |
Mannitol results in decreased expression of PLCL2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 9:3,292,564...3,477,009
Ensembl chr 9:3,292,695...3,477,009
|
|
G |
Plekho1 |
pleckstrin homology domain containing O1 |
increases expression |
ISO |
Mannitol results in increased expression of PLEKHO1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:183,544,487...183,552,928
Ensembl chr 2:183,544,499...183,552,785
|
|
G |
Pou1f1 |
POU class 1 homeobox 1 |
increases expression |
ISO |
Mannitol results in increased expression of POU1F1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr11:3,316,818...3,334,804
Ensembl chr11:3,317,058...3,334,801
|
|
G |
Ppp1r10 |
protein phosphatase 1, regulatory subunit 10 |
decreases expression |
ISO |
Mannitol results in decreased expression of PPP1R10 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr20:2,822,995...2,838,125
Ensembl chr20:2,822,995...2,837,611
|
|
G |
Ppp4c |
protein phosphatase 4, catalytic subunit |
increases expression |
ISO |
Mannitol results in increased expression of PPP4C mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:181,392,899...181,399,703
Ensembl chr 1:181,392,923...181,399,659
|
|
G |
Prkcb |
protein kinase C, beta |
multiple interactions |
ISO |
Mannitol inhibits the reaction [Glucose results in increased expression of PRKCB protein alternative form]; Mannitol inhibits the reaction [Glucose results in increased expression of PRKCB protein] |
CTD |
PMID:16285992 |
|
NCBI chr 1:176,832,173...177,163,539
Ensembl chr 1:176,832,226...177,163,536
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions |
ISO |
Mannitol inhibits the reaction [Glucose results in increased expression of PRKCD protein] |
CTD |
PMID:16285992 |
|
NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Ptger1 |
prostaglandin E receptor 1 |
increases expression |
EXP |
Mannitol results in increased expression of PTGER1 mRNA |
CTD |
PMID:12888618 |
|
NCBI chr19:24,470,258...24,473,687
Ensembl chr19:24,467,532...24,473,559
|
|
G |
Ptger4 |
prostaglandin E receptor 4 |
decreases expression |
EXP |
Mannitol results in decreased expression of PTGER4 mRNA |
CTD |
PMID:12888618 |
|
NCBI chr 2:54,330,563...54,347,451
Ensembl chr 2:54,335,424...54,346,670
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
multiple interactions |
ISO |
benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [Mannitol results in decreased phosphorylation of and results in increased degradation of PTK2 protein]; Mannitol results in decreased phosphorylation of and results in increased degradation of PTK2 protein |
CTD |
PMID:12011046 |
|
NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
|
|
G |
Ralgdsl3 |
ral guanine nucleotide dissociation stimulator like 3 |
increases expression |
ISO |
Mannitol results in increased expression of RGL3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:20,500,846...20,520,471
Ensembl chr 8:20,500,846...20,520,471
|
|
G |
Rbl1 |
RB transcriptional corepressor like 1 |
decreases expression |
ISO |
Mannitol results in decreased expression of RBL1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:145,806,160...145,869,434
Ensembl chr 3:145,807,095...145,869,330
|
|
G |
Rbp2 |
retinol binding protein 2 |
decreases expression |
ISO |
Mannitol results in decreased expression of RBP2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:99,079,293...99,104,489
Ensembl chr 8:99,079,104...99,104,473
|
|
G |
Samd10 |
sterile alpha motif domain containing 10 |
decreases expression |
ISO |
Mannitol results in decreased expression of SAMD10 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:168,700,280...168,704,427
Ensembl chr 3:168,700,284...168,705,248
|
|
G |
Sbsn |
suprabasin |
decreases expression |
ISO |
Mannitol results in decreased expression of SBSN mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:85,978,970...86,006,034
Ensembl chr 1:86,001,567...86,006,034
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
Mannitol inhibits the reaction [Glucose results in increased expression of SELE mRNA]; Mannitol inhibits the reaction [Glucose results in increased expression of SELE protein] |
CTD |
PMID:16285992 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Sgsm3 |
small G protein signaling modulator 3 |
decreases expression |
ISO |
Mannitol results in decreased expression of SGSM3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:112,514,453...112,544,109
Ensembl chr 7:112,514,630...112,544,108
|
|
G |
Slc12a1 |
solute carrier family 12 member 1 |
increases activity multiple interactions |
EXP |
Mannitol results in increased activity of SLC12A1 protein [Mannitol results in increased activity of SLC12A1 protein] which results in increased import of Water |
CTD |
PMID:12433675 |
|
NCBI chr 3:112,406,140...112,482,913
Ensembl chr 3:112,406,140...112,482,899
|
|
G |
Slc2a8 |
solute carrier family 2 member 8 |
decreases expression |
ISO |
Mannitol results in decreased expression of SLC2A8 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:16,274,918...16,284,536
Ensembl chr 3:16,274,925...16,284,464
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
EXP |
Mannitol inhibits the reaction [Vitamin A results in increased phosphorylation of SRC protein] |
CTD |
PMID:16510265 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Stx8 |
syntaxin 8 |
decreases expression |
ISO |
Mannitol results in decreased expression of STX8 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:52,655,643...52,900,048
Ensembl chr10:52,654,990...52,894,993
|
|
G |
Timd4 |
T-cell immunoglobulin and mucin domain containing 4 |
decreases expression |
ISO |
Mannitol results in decreased expression of TIMD4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:31,185,751...31,221,843
Ensembl chr10:31,185,731...31,220,966
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Mannitol inhibits the reaction [Ascorbic Acid promotes the reaction [Quartz results in increased secretion of TNF protein]]; Mannitol inhibits the reaction [Quartz results in increased secretion of TNF protein] |
CTD |
PMID:19298665 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
increases expression |
ISO |
Mannitol results in increased expression of TNFAIP3 mRNA |
CTD |
PMID:21873647 |
|
NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
Mannitol inhibits the reaction [[cupric chloride co-treated with di(2-picolyl)amine-3(bromoacetyl)coumarin] results in increased expression of TP53 protein] |
CTD |
PMID:29803612 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpd52 |
tumor protein D52 |
decreases expression increases expression |
ISO |
Mannitol results in decreased expression of TPD52 mRNA Mannitol results in increased expression of TPD52 mRNA |
CTD |
PMID:21873647 |
|
NCBI chr 2:92,735,365...92,816,079
Ensembl chr 2:92,735,620...92,816,622
|
|
G |
Triml1 |
tripartite motif family-like 1 |
increases expression |
ISO |
Mannitol results in increased expression of TRIML1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr16:48,994,968...49,005,343
Ensembl chr16:48,997,252...49,005,417
|
|
G |
Ulbp1 |
UL16 binding protein 1 |
increases expression |
ISO |
Mannitol results in increased expression of ULBP1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:1,694,255...1,716,160
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
Mannitol inhibits the reaction [Glucose results in increased expression of VCAM1 mRNA]; Mannitol inhibits the reaction [Glucose results in increased expression of VCAM1 protein] |
CTD |
PMID:16285992 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Wdr20 |
WD repeat domain 20 |
decreases expression |
ISO |
Mannitol results in decreased expression of WDR20 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 6:129,751,952...129,821,464
Ensembl chr 6:129,752,014...129,847,339
|
|
G |
Zfp13 |
zinc finger protein 13 |
decreases expression |
ISO |
Mannitol results in decreased expression of ZFP13 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:12,615,455...12,623,615
Ensembl chr10:12,615,190...12,623,615
|
|
G |
Zg16 |
zymogen granule protein 16 |
decreases expression |
ISO |
Mannitol results in decreased expression of ZG16 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:181,657,722...181,660,079
Ensembl chr 1:181,657,722...181,660,079
|
|
|
G |
Fmr1 |
fragile X messenger ribonucleoprotein 1 |
increases abundance |
ISO |
FMR1 5' UTR mutant form results in increased abundance of threitol |
CTD |
PMID:27385396 |
|
NCBI chr X:147,240,239...147,278,057
Ensembl chr X:147,240,301...147,278,050
|
|
|
G |
Plek |
pleckstrin |
multiple interactions |
ISO |
dioleoylphosphatidic acid analog promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased phosphorylation of PLEK protein] |
CTD |
PMID:8928743 |
|
NCBI chr14:91,397,015...91,429,693
Ensembl chr14:91,397,019...91,454,131
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
[1,2-oleoylphosphatidylcholine co-treated with dioleoylphosphatidic acid] binds to SOD1 protein; [1,2-oleoylphosphatidylcholine co-treated with dioleoylphosphatidic acid] binds to SOD1 protein mutant form; [1,2-oleoylphosphatidylcholine co-treated with dioleoylphosphatidic acid] promotes the reaction [SOD1 protein binds to SOD1 protein]; [1,2-oleoylphosphatidylcholine co-treated with dioleoylphosphatidic acid] promotes the reaction [SOD1 protein mutant form binds to SOD1 protein mutant form] |
CTD |
PMID:29649360 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
|
G |
Pon1 |
paraoxonase 1 |
multiple interactions |
ISO |
1,2-dipalmitoylphosphatidylglycerol inhibits the reaction [Copper promotes the reaction [Ascorbic Acid results in decreased activity of PON1 protein]] |
CTD |
PMID:15104111 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
edelfosine inhibits the reaction [Nicotine results in increased phosphorylation of BCL2 protein]; edelfosine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BCL2 protein]; edelfosine promotes the reaction [Cytarabine results in decreased expression of BCL2 protein] |
CTD |
PMID:9295281 PMID:12421819 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
multiple interactions |
ISO |
edelfosine inhibits the reaction [F2RL1 protein promotes the reaction [allyl isothiocyanate results in increased activity of TRPA1 protein]]; edelfosine inhibits the reaction [F2RL1 protein promotes the reaction [cinnamaldehyde results in increased activity of TRPA1 protein]] |
CTD |
PMID:17571167 |
|
NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
edelfosine inhibits the reaction [LEP protein results in increased transport of Calcium] |
CTD |
PMID:20107083 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Plcb2 |
phospholipase C, beta 2 |
multiple interactions |
ISO |
edelfosine inhibits the reaction [Cytarabine affects the localization of PLCB2 protein]; edelfosine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of PLCB2 protein] |
CTD |
PMID:9295281 |
|
NCBI chr 3:105,683,676...105,704,384
Ensembl chr 3:105,684,815...105,704,302
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
edelfosine results in increased expression of PTGS2 protein |
CTD |
PMID:12485854 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Trpa1 |
transient receptor potential cation channel, subfamily A, member 1 |
multiple interactions |
ISO |
edelfosine inhibits the reaction [F2RL1 protein promotes the reaction [allyl isothiocyanate results in increased activity of TRPA1 protein]]; edelfosine inhibits the reaction [F2RL1 protein promotes the reaction [cinnamaldehyde results in increased activity of TRPA1 protein]] |
CTD |
PMID:17571167 |
|
NCBI chr 5:4,379,862...4,434,133
Ensembl chr 5:4,379,999...4,433,570
|
|
|
G |
A2m |
alpha-2-macroglobulin |
increases expression |
EXP |
Glafenine results in increased expression of A2M mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786
|
|
G |
Aadac |
arylacetamide deacetylase |
decreases expression |
EXP |
Glafenine results in decreased expression of AADAC mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:144,163,436...144,186,086
Ensembl chr 2:144,135,319...144,174,734
|
|
G |
Aamdc |
adipogenesis associated, Mth938 domain containing |
decreases expression |
EXP |
Glafenine results in decreased expression of AAMDC mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:151,861,990...151,893,621
Ensembl chr 1:151,845,255...151,892,398
|
|
G |
Abat |
4-aminobutyrate aminotransferase |
decreases expression |
EXP |
Glafenine results in decreased expression of ABAT mRNA |
CTD |
PMID:24136188 |
|
NCBI chr10:6,996,688...7,092,835
Ensembl chr10:6,999,819...7,092,835
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression |
EXP |
Glafenine results in increased expression of ABCA1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases expression |
EXP |
Glafenine results in decreased expression of ABCB11 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
decreases expression |
EXP |
Glafenine results in decreased expression of ABCB1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases expression |
EXP |
Glafenine results in decreased expression of ABCC2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcd3 |
ATP binding cassette subfamily D member 3 |
decreases expression |
EXP |
Glafenine results in decreased expression of ABCD3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:209,852,087...209,905,763
Ensembl chr 2:209,852,087...209,906,020
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
decreases expression |
EXP |
Glafenine results in decreased expression of ABCG5 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abhd1 |
abhydrolase domain containing 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of ABHD1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 6:25,422,526...25,427,514
Ensembl chr 6:25,422,526...25,427,514
|
|
G |
Abhd14b |
abhydrolase domain containing 14b |
decreases expression |
EXP |
Glafenine results in decreased expression of ABHD14B mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 8:107,087,157...107,092,122
Ensembl chr 8:107,088,069...107,092,119
|
|
G |
Abhd2 |
abhydrolase domain containing 2, acylglycerol lipase |
increases expression |
EXP |
Glafenine results in increased expression of ABHD2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:133,217,403...133,298,564
Ensembl chr 1:133,217,375...133,299,061
|
|
G |
Abhd6 |
abhydrolase domain containing 6, acylglycerol lipase |
decreases expression |
EXP |
Glafenine results in decreased expression of ABHD6 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr15:16,859,740...16,907,094
Ensembl chr15:16,859,738...16,906,985
|
|
G |
Abi1 |
abl-interactor 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of ABI1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr17:85,098,837...85,179,829
Ensembl chr17:85,098,550...85,179,792
|
|
G |
Abraxas2 |
abraxas 2, BRISC complex subunit |
decreases expression |
EXP |
Glafenine results in decreased expression of ABRAXAS2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:187,647,078...187,672,660
Ensembl chr 1:187,647,067...187,672,655
|
|
G |
Abtb1 |
ankyrin repeat and BTB domain containing 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of ABTB1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:121,299,302...121,305,667
Ensembl chr 4:121,299,304...121,305,620
|
|
G |
Abtb2 |
ankyrin repeat and BTB domain containing 2 |
decreases expression |
EXP |
Glafenine results in decreased expression of ABTB2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:89,954,726...90,108,549
Ensembl chr 3:89,954,713...90,108,548
|
|
G |
Abtb3 |
ankyrin repeat and BTB domain containing 3 |
decreases expression |
EXP |
Glafenine results in decreased expression of ABTB3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:18,035,151...18,310,718
Ensembl chr 7:18,036,083...18,310,834
|
|
G |
Acaa1a |
acetyl-CoA acyltransferase 1A |
decreases expression |
EXP |
Glafenine results in decreased expression of ACAA1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 8:119,079,401...119,088,626
Ensembl chr 8:119,079,775...119,088,624
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
increases expression |
EXP |
Glafenine results in increased expression of ACACA mRNA |
CTD |
PMID:24136188 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acad10 |
acyl-CoA dehydrogenase family, member 10 |
decreases expression |
EXP |
Glafenine results in decreased expression of ACAD10 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr12:34,901,211...34,943,973
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Acad11 |
acyl-CoA dehydrogenase family, member 11 |
decreases expression |
EXP |
Glafenine results in decreased expression of ACAD11 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 8:104,681,346...104,746,559
Ensembl chr 8:104,681,396...104,746,560
|
|
G |
Acad9 |
acyl-CoA dehydrogenase family, member 9 |
decreases expression |
EXP |
Glafenine results in decreased expression of ACAD9 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:118,943,170...118,966,150
Ensembl chr 2:118,943,174...118,966,547
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
decreases expression |
EXP |
Glafenine results in decreased expression of ACADM mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
|
|
G |
Acads |
acyl-CoA dehydrogenase short chain |
decreases expression |
EXP |
Glafenine results in decreased expression of ACADS mRNA |
CTD |
PMID:24136188 |
|
NCBI chr12:41,493,650...41,502,897
Ensembl chr12:41,493,626...41,502,898
|
|
G |
Acbd5 |
acyl-CoA binding domain containing 5 |
decreases expression |
EXP |
Glafenine results in decreased expression of ACBD5 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr17:85,206,178...85,248,909
Ensembl chr17:85,206,303...85,248,215
|
|
G |
Acer2 |
alkaline ceramidase 2 |
increases expression |
EXP |
Glafenine results in increased expression of ACER2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:101,391,830...101,442,615
Ensembl chr 5:101,391,885...101,442,614
|
|
G |
Ackr3 |
atypical chemokine receptor 3 |
increases expression |
EXP |
Glafenine results in increased expression of ACKR3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 9:90,799,682...90,811,246
Ensembl chr 9:90,799,686...90,811,237
|
|
G |
Acot12 |
acyl-CoA thioesterase 12 |
decreases expression |
EXP |
Glafenine results in decreased expression of ACOT12 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:22,986,867...23,027,538
Ensembl chr 2:22,986,626...23,027,536
|
|
G |
Acot2 |
acyl-CoA thioesterase 2 |
decreases expression |
EXP |
Glafenine results in decreased expression of ACOT2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 6:103,611,738...103,619,404
Ensembl chr 6:103,611,544...103,619,245
|
|
G |
Acot4 |
acyl-CoA thioesterase 4 |
decreases expression |
EXP |
Glafenine results in decreased expression of ACOT4 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 6:103,668,699...103,674,037
Ensembl chr 6:103,668,753...103,673,917
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of ACOX1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of ACSL1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Acsm2 |
acyl-CoA synthetase medium-chain family member 2 |
decreases expression |
EXP |
Glafenine results in decreased expression of ACSM2A mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:173,916,368...173,955,116
Ensembl chr 1:173,916,368...173,955,116
|
|
G |
Acss2 |
acyl-CoA synthetase short-chain family member 2 |
decreases expression |
EXP |
Glafenine results in decreased expression of ACSS2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:144,003,808...144,047,452
Ensembl chr 3:144,004,336...144,059,675
|
|
G |
Actg1 |
actin, gamma 1 |
increases expression |
EXP |
Glafenine results in increased expression of ACTG1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr10:105,619,738...105,622,587
Ensembl chr10:105,619,737...105,624,232 Ensembl chr 3:105,619,737...105,624,232
|
|
G |
Adck5 |
aarF domain containing kinase 5 |
decreases expression |
EXP |
Glafenine results in decreased expression of ADCK5 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:108,301,623...108,319,439
Ensembl chr 7:108,301,415...108,319,436
|
|
G |
Adh4 |
alcohol dehydrogenase 4 (class II), pi polypeptide |
decreases expression |
EXP |
Glafenine results in decreased expression of ADH4 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591
|
|
G |
Adhfe1 |
alcohol dehydrogenase, iron containing, 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of ADHFE1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:9,705,966...9,732,580
Ensembl chr 5:9,705,970...9,732,517
|
|
G |
Adipor2 |
adiponectin receptor 2 |
decreases expression |
EXP |
Glafenine results in decreased expression of ADIPOR2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:152,524,604...152,588,848
Ensembl chr 4:152,524,623...152,559,355
|
|
G |
Adk |
adenosine kinase |
decreases expression |
EXP |
Glafenine results in decreased expression of ADK mRNA |
CTD |
PMID:24136188 |
|
NCBI chr15:2,863,241...3,246,453
Ensembl chr15:2,863,244...3,246,510
|
|
G |
Adss1 |
adenylosuccinate synthase 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of ADSS1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 6:131,679,795...131,702,012
Ensembl chr 6:131,679,701...131,701,998
|
|
G |
Adtrp |
androgen-dependent TFPI-regulating protein |
decreases expression |
EXP |
Glafenine results in decreased expression of ADTRP mRNA |
CTD |
PMID:24136188 |
|
NCBI chr17:22,907,758...22,993,834
Ensembl chr17:22,930,740...22,993,826
|
|
G |
Afm |
afamin |
decreases expression |
EXP |
Glafenine results in decreased expression of AFM mRNA |
CTD |
PMID:24136188 |
|
NCBI chr14:17,531,022...17,563,868
Ensembl chr14:17,531,024...17,563,870
|
|
G |
Afmid |
arylformamidase |
decreases expression |
EXP |
Glafenine results in decreased expression of AFMID mRNA |
CTD |
PMID:24136188 |
|
NCBI chr10:103,046,129...103,061,718
Ensembl chr10:103,046,180...103,061,718
|
|
G |
Agmat |
agmatinase |
decreases expression |
EXP |
Glafenine results in decreased expression of AGMAT mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:154,043,665...154,074,278
Ensembl chr 5:154,060,151...154,074,276
|
|
G |
Agmo |
alkylglycerol monooxygenase |
decreases expression |
EXP |
Glafenine results in decreased expression of AGMO mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 6:53,986,236...54,317,838
Ensembl chr 6:53,986,292...54,317,623
|
|
G |
Ahcy |
adenosylhomocysteinase |
decreases expression |
EXP |
Glafenine results in decreased expression of AHCY mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:143,569,134...143,584,359
Ensembl chr 3:143,569,094...143,584,393
|
|
G |
Aimp2 |
aminoacyl tRNA synthetase complex-interacting multifunctional protein 2 |
increases expression |
EXP |
Glafenine results in increased expression of AIMP2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr12:10,701,194...10,710,772
Ensembl chr12:10,701,194...10,710,769
|
|
G |
Ak3 |
adenylate kinase 3 |
decreases expression |
EXP |
Glafenine results in decreased expression of AK3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:226,737,472...226,764,647
Ensembl chr 1:226,739,318...226,764,625
|
|
G |
Akr1a1 |
aldo-keto reductase family 1 member A1 |
increases expression |
EXP |
Glafenine results in increased expression of AKR1A1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
decreases expression |
EXP |
Glafenine results in decreased expression of AKR1C1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
AKR1C3l1 |
aldo-keto reductase family 1 member C3-like 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of AKR1C3L1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr17:65,847,580...65,881,488
Ensembl chr17:65,835,634...65,881,488
|
|
G |
Akr1e2 |
aldo-keto reductase family 1, member E2 |
decreases expression |
EXP |
Glafenine results in decreased expression of AKR1E2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr17:65,735,909...65,750,441
Ensembl chr17:65,735,943...65,750,441
|
|
G |
Akr7a2 |
aldo-keto reductase family 7, member A2 |
decreases expression |
EXP |
Glafenine results in decreased expression of AKR7A2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909
|
|
G |
Akr7a3 |
aldo-keto reductase family 7 member A3 |
decreases expression |
EXP |
Glafenine results in decreased expression of AKR7A3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of ALAS1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
decreases expression |
EXP |
Glafenine results in decreased expression of ALDH1A1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh1l1 |
aldehyde dehydrogenase 1 family, member L1 |
decreases expression |
EXP |
Glafenine results in decreased expression of ALDH1L1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:123,059,989...123,106,471
Ensembl chr 4:123,060,008...123,106,465
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
decreases expression |
EXP |
Glafenine results in decreased expression of ALDH2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Aldh3a2 |
aldehyde dehydrogenase 3 family, member A2 |
decreases expression |
EXP |
Glafenine results in decreased expression of ALDH3A2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr10:45,928,313...45,949,366
Ensembl chr10:45,908,524...45,949,281
|
|
G |
Aldh4a1 |
aldehyde dehydrogenase 4 family, member A1 |
decreases expression |
EXP |
Glafenine results in decreased expression of ALDH4A1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:151,880,002...151,905,491
Ensembl chr 5:151,830,701...151,925,345
|
|
G |
Aldh5a1 |
aldehyde dehydrogenase 5 family, member A1 |
decreases expression |
EXP |
Glafenine results in decreased expression of ALDH5A1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr17:40,132,339...40,158,677
Ensembl chr17:40,130,883...40,158,677
|
|
G |
Aldh6a1 |
aldehyde dehydrogenase 6 family, member A1 |
decreases expression |
EXP |
Glafenine results in decreased expression of ALDH6A1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 6:104,077,975...104,098,636
Ensembl chr 6:104,077,979...104,098,656
|
|
G |
Aldh9a1 |
aldehyde dehydrogenase 9 family, member A1 |
decreases expression |
EXP |
Glafenine results in decreased expression of ALDH9A1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr13:79,505,738...79,522,539
Ensembl chr13:79,505,695...79,540,568
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
increases expression |
EXP |
Glafenine results in increased expression of ALDOA mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182
|
|
G |
Alg12 |
ALG12, alpha-1,6-mannosyltransferase |
increases expression |
EXP |
Glafenine results in increased expression of ALG12 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:119,895,112...119,909,488
Ensembl chr 7:119,895,120...119,909,458
|
|
G |
Alg2 |
ALG2, alpha-1,3/1,6-mannosyltransferase |
increases expression |
EXP |
Glafenine results in increased expression of ALG2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:61,768,738...61,773,297
Ensembl chr 5:61,768,740...61,773,297
|
|
G |
Alg3 |
ALG3, alpha-1,3- mannosyltransferase |
increases expression |
EXP |
Glafenine results in increased expression of ALG3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr11:80,300,487...80,306,014
Ensembl chr11:80,300,498...80,307,912
|
|
G |
Amacr |
alpha-methylacyl-CoA racemase |
decreases expression |
EXP |
Glafenine results in decreased expression of AMACR mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:59,946,158...59,958,255
Ensembl chr 2:59,946,153...59,958,255
|
|
G |
Amigo3 |
adhesion molecule with Ig like domain 3 |
increases expression |
EXP |
Glafenine results in increased expression of AMIGO3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 8:108,741,899...108,743,425
Ensembl chr 8:108,693,060...108,744,555
|
|
G |
Amy1 |
amylase alpha 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of AMY1A mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:201,382,678...201,397,487
Ensembl chr 2:201,382,675...201,397,816
|
|
G |
Ang |
angiogenin |
decreases expression |
EXP |
Glafenine results in decreased expression of ANG mRNA |
CTD |
PMID:24136188 |
|
NCBI chr15:24,312,711...24,323,361
|
|
G |
Angptl3 |
angiopoietin-like 3 |
decreases expression |
EXP |
Glafenine results in decreased expression of ANGPTL3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:113,703,007...113,710,044
Ensembl chr 5:113,703,012...113,709,957
|
|
G |
Ankrd24 |
ankyrin repeat domain 24 |
increases expression |
EXP |
Glafenine results in increased expression of ANKRD24 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:8,061,634...8,081,142
Ensembl chr 7:8,061,953...8,081,142
|
|
G |
Ankrd46 |
ankyrin repeat domain 46 |
decreases expression |
EXP |
Glafenine results in decreased expression of ANKRD46 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:67,647,202...67,668,180
Ensembl chr 7:67,647,204...67,668,132
|
|
G |
Anks4b |
ankyrin repeat and sterile alpha motif domain containing 4B |
decreases expression |
EXP |
Glafenine results in decreased expression of ANKS4B mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:174,534,195...174,557,798
Ensembl chr 1:174,547,473...174,557,797
|
|
G |
Antxr2 |
ANTXR cell adhesion molecule 2 |
decreases expression |
EXP |
Glafenine results in decreased expression of ANTXR2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr14:11,541,718...11,682,110
Ensembl chr14:11,541,772...11,682,094
|
|
G |
Anxa4 |
annexin A4 |
decreases expression |
EXP |
Glafenine results in decreased expression of ANXA4 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161
|
|
G |
Apeg3 |
antisense paternally expressed gene 3 |
increases expression |
EXP |
Glafenine results in increased expression of APEG3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:67,121,402...67,122,333
Ensembl chr 1:67,121,900...67,122,181 Ensembl chr 1:67,121,900...67,122,181
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
increases expression |
EXP |
Glafenine results in increased expression of APEX1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Apmap |
adipocyte plasma membrane associated protein |
decreases expression |
EXP |
Glafenine results in decreased expression of APMAP mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:139,409,021...139,437,296
Ensembl chr 3:139,409,022...139,437,341
|
|
G |
Apoa2 |
apolipoprotein A2 |
decreases expression |
EXP |
Glafenine results in decreased expression of APOA2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355
|
|
G |
Appbp2 |
amyloid beta precursor protein binding protein 2 |
decreases expression |
EXP |
Glafenine results in decreased expression of APPBP2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr10:70,057,774...70,099,877
Ensembl chr10:70,057,774...70,099,835
|
|
G |
Aprt |
adenine phosphoribosyl transferase |
increases expression |
EXP |
Glafenine results in increased expression of APRT mRNA |
CTD |
PMID:24136188 |
|
NCBI chr19:50,626,201...50,628,491
Ensembl chr19:50,626,202...50,628,431
|
|
G |
Arf4 |
ADP-ribosylation factor 4 |
increases expression |
EXP |
Glafenine results in increased expression of ARF4 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr16:1,896,692...1,913,267
Ensembl chr16:1,896,546...1,913,261
|
|
G |
Arfgap3 |
ADP-ribosylation factor GTPase activating protein 3 |
increases expression |
EXP |
Glafenine results in increased expression of ARFGAP3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:114,432,873...114,479,206
Ensembl chr 7:114,432,873...114,479,208
|
|
G |
Arfgef1 |
ADP ribosylation factor guanine nucleotide exchange factor 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of ARFGEF1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:8,982,061...9,076,326
Ensembl chr 5:8,981,540...9,076,326
|
|
G |
Arfip2 |
ADP-ribosylation factor interacting protein 2 |
increases expression |
EXP |
Glafenine results in increased expression of ARFIP2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:159,974,255...159,980,398
Ensembl chr 1:159,974,201...159,980,336
|
|
G |
Arhgap1 |
Rho GTPase activating protein 1 |
increases expression |
EXP |
Glafenine results in increased expression of ARHGAP1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:77,621,377...77,643,400
Ensembl chr 3:77,620,655...77,643,396
|
|
G |
Arhgap18 |
Rho GTPase activating protein 18 |
decreases expression |
EXP |
Glafenine results in decreased expression of ARHGAP18 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:18,403,531...18,637,306
Ensembl chr 1:18,403,537...18,637,256
|
|
G |
Arhgap24 |
Rho GTPase activating protein 24 |
decreases expression |
EXP |
Glafenine results in decreased expression of ARHGAP24 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr14:6,800,624...7,183,877
Ensembl chr14:6,800,631...7,183,823
|
|
G |
Arl6ip1 |
ADP-ribosylation factor like GTPase 6 interacting protein 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of ARL6IP1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:172,430,475...172,439,990
Ensembl chr 1:172,430,489...172,439,994
|
|
G |
Arl6ip4 |
ADP-ribosylation factor like GTPase 6 interacting protein 4 |
increases expression |
EXP |
Glafenine results in increased expression of ARL6IP4 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr12:32,479,623...32,481,768
Ensembl chr12:32,479,625...32,481,799
|
|
G |
Armc9 |
armadillo repeat containing 9 |
increases expression |
EXP |
Glafenine results in increased expression of ARMC9 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 9:86,802,791...86,928,611
Ensembl chr 9:86,802,868...86,928,860
|
|
G |
Armcx3 |
armadillo repeat containing, X-linked 3 |
increases expression |
EXP |
Glafenine results in increased expression of ARMCX3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr X:97,937,115...97,942,098
Ensembl chr X:97,936,999...97,942,098
|
|
G |
Arpc1b |
actin related protein 2/3 complex, subunit 1B |
increases expression |
EXP |
Glafenine results in increased expression of ARPC1B mRNA |
CTD |
PMID:24136188 |
|
NCBI chr12:9,482,176...9,495,772
Ensembl chr12:9,480,831...9,495,747
|
|
G |
Arpc5l |
actin related protein 2/3 complex, subunit 5-like |
increases expression |
EXP |
Glafenine results in increased expression of ARPC5L mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:22,758,710...22,767,520
Ensembl chr 3:22,759,876...22,767,538 Ensembl chr 9:22,759,876...22,767,538
|
|
G |
Asl |
argininosuccinate lyase |
decreases expression |
EXP |
Glafenine results in decreased expression of ASL mRNA |
CTD |
PMID:24136188 |
|
NCBI chr12:26,659,664...26,677,136
Ensembl chr12:26,659,565...26,679,662
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of ASS1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression |
EXP |
Glafenine results in increased expression of ATF4 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atg13 |
autophagy related 13 |
increases expression |
EXP |
Glafenine results in increased expression of ATG13 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:77,647,069...77,681,028
Ensembl chr 3:77,645,790...77,681,043
|
|
G |
Atg16l2 |
autophagy related 16-like 2 |
increases expression |
EXP |
Glafenine results in increased expression of ATG16L2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:155,687,386...155,703,419
Ensembl chr 1:155,684,564...155,703,420
|
|
G |
Atg2b |
autophagy related 2B |
decreases expression |
EXP |
Glafenine results in decreased expression of ATG2B mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 6:124,522,283...124,592,412
Ensembl chr 6:124,525,523...124,592,015
|
|
G |
Atl2 |
atlastin GTPase 2 |
decreases expression |
EXP |
Glafenine results in decreased expression of ATL2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 6:15,139,071...15,180,421
Ensembl chr 6:15,139,044...15,180,421
|
|
G |
Atosa |
atos homolog A |
decreases expression |
EXP |
Glafenine results in decreased expression of ATOSA mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 8:75,694,828...75,772,565
Ensembl chr 8:75,695,022...75,772,549
|
|
G |
Atp11a |
ATPase phospholipid transporting 11A |
decreases expression |
EXP |
Glafenine results in decreased expression of ATP11A mRNA |
CTD |
PMID:24136188 |
|
NCBI chr16:76,657,752...76,767,640
Ensembl chr16:76,657,752...76,767,640
|
|
G |
Atp11c |
ATPase phospholipid transporting 11C |
decreases expression |
EXP |
Glafenine results in decreased expression of ATP11C mRNA |
CTD |
PMID:24136188 |
|
NCBI chr X:138,564,459...138,752,116
Ensembl chr X:138,565,836...138,751,204
|
|
G |
Atp1b1 |
ATPase Na+/K+ transporting subunit beta 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of ATP1B1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
increases expression |
EXP |
Glafenine results in increased expression of ATP2A2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
|
|
G |
Atp5mc1 |
ATP synthase membrane subunit c locus 1 |
increases expression |
EXP |
Glafenine results in increased expression of ATP5MC1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr10:81,024,056...81,026,780
Ensembl chr10:81,023,925...81,027,124 Ensembl chr10:81,023,925...81,027,124
|
|
G |
Atrn |
attractin |
decreases expression |
EXP |
Glafenine results in decreased expression of ATRN mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:118,110,320...118,244,326
Ensembl chr 3:118,110,229...118,244,322
|
|
G |
Atxn2 |
ataxin 2 |
decreases expression |
EXP |
Glafenine results in decreased expression of ATXN2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr12:34,754,132...34,851,175
Ensembl chr12:34,754,137...34,851,479
|
|
G |
Aurkaip1 |
aurora kinase A interacting protein 1 |
increases expression |
EXP |
Glafenine results in increased expression of AURKAIP1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:166,435,177...166,436,888
Ensembl chr 5:166,417,508...166,436,882
|
|
G |
B2m |
beta-2 microglobulin |
decreases expression |
EXP |
Glafenine results in decreased expression of B2M mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766
|
|
G |
B4galt1 |
beta-1,4-galactosyltransferase 1 |
increases expression |
EXP |
Glafenine results in increased expression of B4GALT1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:55,935,614...55,982,461
Ensembl chr 5:55,935,615...55,982,461
|
|
G |
B4gat1 |
beta-1,4-glucuronyltransferase 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of B4GAT1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:202,343,268...202,345,490
Ensembl chr 1:202,343,240...202,346,065
|
|
G |
Baat |
bile acid CoA:amino acid N-acyltransferase |
decreases expression |
EXP |
Glafenine results in decreased expression of BAAT mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:63,851,668...63,860,641
Ensembl chr 5:63,850,705...63,860,685
|
|
G |
Babam1 |
BRISC and BRCA1 A complex member 1 |
increases expression |
EXP |
Glafenine results in increased expression of BABAM1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr16:18,068,830...18,074,938
Ensembl chr16:18,068,884...18,074,923
|
|
G |
Basp1 |
brain abundant, membrane attached signal protein 1 |
increases expression |
EXP |
Glafenine results in increased expression of BASP1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:75,816,130...75,863,801
Ensembl chr 2:75,816,122...75,864,043
|
|
G |
Bbln |
bublin coiled coil protein |
increases expression |
EXP |
Glafenine results in increased expression of BBLN mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:15,674,577...15,677,322
Ensembl chr 3:15,674,580...15,677,374
|
|
G |
Bbox1 |
gamma-butyrobetaine hydroxylase 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of BBOX1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:96,822,654...96,871,786
Ensembl chr 3:96,822,655...96,871,458
|
|
G |
Bbs2 |
Bardet-Biedl syndrome 2 |
decreases expression |
EXP |
Glafenine results in decreased expression of BBS2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr19:10,909,653...10,944,998
Ensembl chr19:10,909,619...10,944,993
|
|
G |
Bcl3 |
BCL3, transcription coactivator |
increases expression |
EXP |
Glafenine results in increased expression of BCL3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607
|
|
G |
Bet1l |
Bet1 golgi vesicular membrane trafficking protein-like |
increases expression |
EXP |
Glafenine results in increased expression of BET1L mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:195,931,407...195,935,072
Ensembl chr 1:195,931,411...195,935,040
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
increases expression |
EXP |
Glafenine results in increased expression of BHLHE40 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774
|
|
G |
Bhmt |
betaine-homocysteine S-methyltransferase |
decreases expression |
EXP |
Glafenine results in decreased expression of BHMT mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:24,859,871...24,879,449
Ensembl chr 2:24,859,873...24,879,742
|
|
G |
Bhmt2 |
betaine-homocysteine S-methyltransferase 2 |
decreases expression |
EXP |
Glafenine results in decreased expression of BHMT2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:24,895,525...24,912,475
Ensembl chr 2:24,895,533...24,912,475
|
|
G |
Bloc1s5 |
biogenesis of lysosomal organelles complex 1 subunit 5 |
decreases expression |
EXP |
Glafenine results in decreased expression of BLOC1S5 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr17:26,171,965...26,197,276
Ensembl chr17:26,172,018...26,197,251
|
|
G |
Blvrb |
biliverdin reductase B |
decreases expression |
EXP |
Glafenine results in decreased expression of BLVRB mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:82,738,646...82,756,312
Ensembl chr 1:82,738,695...82,770,375
|
|
G |
Bnip1 |
BCL2 interacting protein 1 |
increases expression |
EXP |
Glafenine results in increased expression of BNIP1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr10:16,386,876...16,399,124
Ensembl chr10:16,386,841...16,399,157
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
decreases expression |
EXP |
Glafenine results in decreased expression of BNIP3L mRNA |
CTD |
PMID:24136188 |
|
NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803
|
|
G |
Bola2-ps4 |
bolA family member 2, pseudogene 4 |
increases expression |
EXP |
Glafenine results in increased expression of BOLA2-PS4 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:153,272,435...153,272,781
|
|
G |
Bola3 |
bolA family member 3 |
increases expression |
EXP |
Glafenine results in increased expression of BOLA3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:115,853,350...115,862,797
Ensembl chr 4:115,853,350...115,862,797
|
|
G |
Bop1 |
BOP1 ribosomal biogenesis factor |
increases expression |
EXP |
Glafenine results in increased expression of BOP1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:108,172,062...108,195,875
Ensembl chr 7:108,172,066...108,195,931
|
|
G |
Borcs7 |
BLOC-1 related complex subunit 7 |
increases expression |
EXP |
Glafenine results in increased expression of BORCS7 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:245,564,347...245,578,182
Ensembl chr 1:245,564,369...245,579,343
|
|
G |
Bphl |
biphenyl hydrolase like |
decreases expression |
EXP |
Glafenine results in decreased expression of BPHL mRNA |
CTD |
PMID:24136188 |
|
NCBI chr17:30,800,939...30,837,277
Ensembl chr17:30,799,629...30,837,288
|
|
G |
Brd3 |
bromodomain containing 3 |
decreases expression |
EXP |
Glafenine results in decreased expression of BRD3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:10,773,163...10,829,675
Ensembl chr 3:10,775,272...10,829,577
|
|
G |
Brix1 |
biogenesis of ribosomes BRX1 |
increases expression |
EXP |
Glafenine results in increased expression of BRIX1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:59,450,608...59,461,486
Ensembl chr 2:59,450,614...59,461,495
|
|
G |
Btbd1 |
BTB domain containing 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of BTBD1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:135,734,549...135,773,067
Ensembl chr 1:135,734,589...135,771,981
|
|
G |
Btbd6 |
BTB domain containing 6 |
decreases expression |
EXP |
Glafenine results in decreased expression of BTBD6 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 6:132,058,094...132,060,603
Ensembl chr 6:132,058,096...132,060,587
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
EXP |
Glafenine results in increased expression of BTG2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
Btg3 |
BTG anti-proliferation factor 3 |
increases expression |
EXP |
Glafenine results in increased expression of BTG3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr11:17,030,156...17,046,069
Ensembl chr11:17,030,160...17,046,170
|
|
G |
Bysl |
bystin-like |
increases expression |
EXP |
Glafenine results in increased expression of BYSL mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 9:13,382,806...13,392,557
Ensembl chr 9:13,382,557...13,394,339
|
|
G |
C10h17orf58 |
similar to human chromosome 17 open reading frame 58 |
increases expression |
EXP |
Glafenine results in increased expression of C10H17ORF58 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr10:91,972,938...91,977,606
Ensembl chr10:91,972,410...91,977,602
|
|
G |
C15h14orf119 |
similar to human chromosome 14 open reading frame 119 |
increases expression |
EXP |
Glafenine results in increased expression of C15H14ORF119 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr15:28,146,368...28,151,422
Ensembl chr15:28,146,333...28,155,180
|
|
G |
C18h18orf32 |
similar to human chromosome 18 open reading frame 32 |
increases expression |
EXP |
Glafenine results in increased expression of C18H18ORF32 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr18:68,586,278...68,594,851
Ensembl chr18:68,586,211...68,596,787
|
|
G |
C1qbp |
complement C1q binding protein |
increases expression |
EXP |
Glafenine results in increased expression of C1QBP mRNA |
CTD |
PMID:24136188 |
|
NCBI chr10:55,699,954...55,704,605
Ensembl chr10:55,699,954...55,704,649
|
|
G |
C4bpb |
complement component 4 binding protein, beta |
increases expression |
EXP |
Glafenine results in increased expression of C4BPB mRNA |
CTD |
PMID:24136188 |
|
NCBI chr13:42,120,798...42,131,515
Ensembl chr13:42,120,798...42,131,817
|
|
G |
C5 |
complement C5 |
increases expression |
EXP |
Glafenine results in increased expression of C5 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994
|
|
G |
C5h1orf122 |
similar to human chromosome 1 open reading frame 122 |
increases expression |
EXP |
Glafenine results in increased expression of C5H1ORF122 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:137,109,093...137,110,130
Ensembl chr 5:137,108,633...137,110,929
|
|
G |
C8h11orf54 |
similar to human chromosome 11 open reading frame 54 |
decreases expression |
EXP |
Glafenine results in decreased expression of C8H11ORF54 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 8:12,123,839...12,146,412
Ensembl chr 8:12,123,823...12,146,473
|
|
G |
C9 |
complement C9 |
increases expression |
EXP |
Glafenine results in increased expression of C9 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:55,573,094...55,621,345
Ensembl chr 2:55,572,992...55,621,338
|
|
G |
Cad |
carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase |
increases expression |
EXP |
Glafenine results in increased expression of CAD mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 6:25,292,133...25,315,078
Ensembl chr 6:25,292,133...25,319,861
|
|
G |
Calm1 |
calmodulin 1 |
increases expression |
EXP |
Glafenine results in increased expression of CALM1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 6:119,487,691...119,495,759
Ensembl chr 6:119,487,621...119,498,227
|
|
G |
Calr |
calreticulin |
increases expression |
EXP |
Glafenine results in increased expression of CALR mRNA |
CTD |
PMID:24136188 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Calu |
calumenin |
increases expression |
EXP |
Glafenine results in increased expression of CALU mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:57,949,086...57,976,589
Ensembl chr 4:57,948,997...57,976,593
|
|
G |
Caprin1 |
cell cycle associated protein 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of CAPRIN1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:90,152,305...90,230,447
Ensembl chr 3:90,153,620...90,230,502
|
|
G |
Car14 |
carbonic anhydrase 14 |
decreases expression |
EXP |
Glafenine results in decreased expression of CAR14 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:183,442,263...183,449,231
Ensembl chr 2:183,441,667...183,449,693
|
|
G |
Car3 |
carbonic anhydrase 3 |
decreases expression |
EXP |
Glafenine results in decreased expression of CAR3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
G |
Car5a |
carbonic anhydrase 5A |
decreases expression |
EXP |
Glafenine results in decreased expression of CAR5A mRNA |
CTD |
PMID:24136188 |
|
NCBI chr19:49,973,092...50,002,948
Ensembl chr19:49,973,107...50,002,906
|
|
G |
Car8 |
carbonic anhydrase 8 |
increases expression |
EXP |
Glafenine results in increased expression of CAR8 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:21,302,940...21,402,395
Ensembl chr 5:21,305,383...21,402,374
|
|
G |
Cars1 |
cysteinyl-tRNA synthetase 1 |
increases expression |
EXP |
Glafenine results in increased expression of CARS1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:198,753,689...198,796,016
Ensembl chr 1:198,753,691...198,795,941
|
|
G |
Cars2 |
cysteinyl-tRNA synthetase 2, mitochondrial |
decreases expression |
EXP |
Glafenine results in decreased expression of CARS2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr16:77,945,468...77,987,163
Ensembl chr16:77,950,008...77,987,772
|
|
G |
Cat |
catalase |
decreases expression |
EXP |
Glafenine results in decreased expression of CAT mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cav2 |
caveolin 2 |
increases expression |
EXP |
Glafenine results in increased expression of CAV2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:45,616,766...45,624,144
Ensembl chr 4:45,616,712...45,624,244
|
|
G |
Cbr4 |
carbonyl reductase 4 |
decreases expression |
EXP |
Glafenine results in decreased expression of CBR4 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr16:28,629,928...28,684,230
Ensembl chr16:28,617,224...28,645,712
|
|
G |
Ccdc125 |
coiled-coil domain containing 125 |
increases expression |
EXP |
Glafenine results in increased expression of CCDC125 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:31,809,120...31,835,538
Ensembl chr 2:31,809,228...31,850,152
|
|
G |
Ccdc134 |
coiled-coil domain containing 134 |
increases expression |
EXP |
Glafenine results in increased expression of CCDC134 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:113,644,557...113,659,050
Ensembl chr 7:113,644,639...113,659,050
|
|
G |
Ccdc167 |
coiled-coil domain containing 167 |
increases expression |
EXP |
Glafenine results in increased expression of CCDC167 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr20:7,763,927...7,782,090
Ensembl chr20:7,751,782...7,781,613
|
|
G |
Ccdc28a |
coiled-coil domain containing 28A |
decreases expression |
EXP |
Glafenine results in decreased expression of CCDC28A mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:12,857,668...12,872,944
Ensembl chr 1:12,857,666...12,873,003
|
|
G |
Ccdc86 |
coiled-coil domain containing 86 |
increases expression |
EXP |
Glafenine results in increased expression of CCDC86 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:207,590,167...207,596,547
Ensembl chr 1:207,590,168...207,596,544
|
|
G |
Ccng2 |
cyclin G2 |
decreases expression |
EXP |
Glafenine results in decreased expression of CCNG2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
|
|
G |
Ccni |
cyclin I |
decreases expression |
EXP |
Glafenine results in decreased expression of CCNI mRNA |
CTD |
PMID:24136188 |
|
NCBI chr14:14,879,698...14,902,510
Ensembl chr14:14,879,717...14,902,510
|
|
G |
Cd2bp2 |
Cd2 (cytoplasmic tail) binding protein 2 |
increases expression |
EXP |
Glafenine results in increased expression of CD2BP2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:181,809,399...181,815,269
Ensembl chr 1:181,809,406...181,813,448
|
|
G |
Cd48 |
Cd48 molecule |
increases expression |
EXP |
Glafenine results in increased expression of CD48 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr13:84,184,884...84,209,144
Ensembl chr13:84,185,532...84,209,142
|
|
G |
Cd59b |
CD59b molecule |
decreases expression |
EXP |
Glafenine results in decreased expression of CD59 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:90,459,085...90,477,571
Ensembl chr 3:90,459,162...90,478,847
|
|
G |
Cdadc1 |
cytidine and dCMP deaminase domain containing 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of CDADC1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr15:33,726,590...33,755,611
Ensembl chr15:33,723,435...33,755,576
|
|
G |
Cdc42se1 |
CDC42 small effector 1 |
increases expression |
EXP |
Glafenine results in increased expression of CDC42SE1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:182,805,691...182,813,520
Ensembl chr 2:182,804,925...182,814,028
|
|
G |
Cdc5l |
cell division cycle 5-like |
decreases expression |
EXP |
Glafenine results in decreased expression of CDC5L mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 9:15,564,949...15,603,453
Ensembl chr 9:15,564,767...15,603,450
|
|
G |
Cdh2 |
cadherin 2 |
decreases expression |
EXP |
Glafenine results in decreased expression of CDH2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdip1 |
cell death-inducing p53 target 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of CDIP1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr10:10,773,538...10,796,979
Ensembl chr10:10,774,705...10,796,980
|
|
G |
Cdk2ap1 |
cyclin-dependent kinase 2 associated protein 1 |
increases expression |
EXP |
Glafenine results in increased expression of CDK2AP1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr12:32,249,752...32,258,483
Ensembl chr12:32,249,747...32,258,479
|
|
G |
Cdk2ap2 |
cyclin-dependent kinase 2 associated protein 2 |
increases expression |
EXP |
Glafenine results in increased expression of CDK2AP2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:201,391,056...201,393,137
Ensembl chr 1:201,391,466...201,393,137
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
increases expression |
EXP |
Glafenine results in increased expression of CDK4 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
EXP |
Glafenine results in increased expression of CDKN1A mRNA |
CTD |
PMID:24136188 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
decreases expression |
EXP |
Glafenine results in decreased expression of CDKN1B mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
decreases expression |
EXP |
Glafenine results in decreased expression of CDKN3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945
|
|
G |
Cdo1 |
cysteine dioxygenase type 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of CDO1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr18:39,432,473...39,447,253
Ensembl chr18:39,432,474...39,447,296
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of CEACAM1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:81,043,595...81,060,050
Ensembl chr 1:81,043,595...81,059,992
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
increases expression |
EXP |
Glafenine results in increased expression of CEBPD mRNA |
CTD |
PMID:24136188 |
|
NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
|
|
G |
Cemip2 |
cell migration inducing hyaluronidase 2 |
increases expression |
EXP |
Glafenine results in increased expression of CEMIP2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:219,330,295...219,407,760
Ensembl chr 1:219,337,985...219,407,760
|
|
G |
Cept1 |
choline/ethanolamine phosphotransferase 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of CEPT1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:193,994,220...194,036,141
Ensembl chr 2:193,993,447...194,035,578
|
|
G |
Ces1d |
carboxylesterase 1D |
decreases expression |
EXP |
Glafenine results in decreased expression of CES1D mRNA |
CTD |
PMID:24136188 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Chac2 |
ChaC glutathione specific gamma-glutamylcyclotransferase 2 |
decreases expression |
EXP |
Glafenine results in decreased expression of CHAC2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr14:104,720,754...104,728,305
Ensembl chr14:104,720,758...104,728,301
|
|
G |
Chchd6 |
coiled-coil-helix-coiled-coil-helix domain containing 6 |
increases expression |
EXP |
Glafenine results in increased expression of CHCHD6 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:121,803,501...122,024,209
Ensembl chr 4:121,792,717...122,024,216
|
|
G |
Chid1 |
chitinase domain containing 1 |
increases expression |
EXP |
Glafenine results in increased expression of CHID1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:196,594,357...196,629,700
Ensembl chr 1:196,587,509...196,629,606
|
|
G |
Chmp4c |
charged multivesicular body protein 4C |
decreases expression |
EXP |
Glafenine results in decreased expression of CHMP4C mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:91,391,729...91,428,652
Ensembl chr 2:91,388,530...91,428,668
|
|
G |
Chpf2 |
chondroitin polymerizing factor 2 |
increases expression |
EXP |
Glafenine results in increased expression of CHPF2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:10,578,470...10,585,940
Ensembl chr 4:10,580,462...10,585,916
|
|
G |
Cic |
capicua transcriptional repressor |
increases expression |
EXP |
Glafenine results in increased expression of CIC mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:80,853,920...80,880,537
Ensembl chr 1:80,853,920...80,880,532
|
|
G |
Cinp |
cyclin-dependent kinase 2-interacting protein |
increases expression |
EXP |
Glafenine results in increased expression of CINP mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 6:129,878,618...129,899,575
Ensembl chr 6:129,885,570...129,899,480
|
|
G |
Cisd2 |
CDGSH iron sulfur domain 2 |
increases expression |
EXP |
Glafenine results in increased expression of CISD2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:223,828,937...223,853,768
Ensembl chr 2:223,828,937...223,868,946
|
|
G |
Cks1b |
CDC28 protein kinase regulatory subunit 1B |
increases expression |
EXP |
Glafenine results in increased expression of CKS1B mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:174,833,025...174,837,614
Ensembl chr 2:174,833,050...174,837,636
|
|
G |
Clcn4 |
chloride voltage-gated channel 4 |
decreases expression |
EXP |
Glafenine results in decreased expression of CLCN4 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr X:23,729,194...23,795,391
Ensembl chr X:23,729,338...23,793,238
|
|
G |
Clic1 |
chloride intracellular channel 1 |
increases expression |
EXP |
Glafenine results in increased expression of CLIC1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr20:3,764,867...3,773,711
Ensembl chr20:3,761,461...3,773,712
|
|
G |
Clpx |
caseinolytic mitochondrial matrix peptidase chaperone subunit X |
decreases expression |
EXP |
Glafenine results in decreased expression of CLPX mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 8:65,805,460...65,845,643
Ensembl chr 8:65,805,511...65,845,082
|
|
G |
Cmbl |
carboxymethylenebutenolidase homolog |
decreases expression |
EXP |
Glafenine results in decreased expression of CMBL mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:82,569,257...82,591,007
Ensembl chr 2:82,571,888...82,591,009
|
|
G |
Cmtr1 |
cap methyltransferase 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of CMTR1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr20:7,722,729...7,782,579
Ensembl chr20:7,709,713...7,766,302
|
|
G |
Cnn2 |
calponin 2 |
increases expression |
EXP |
Glafenine results in increased expression of CNN2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:9,712,505...9,719,678
Ensembl chr 7:9,712,516...9,719,656
|
|
G |
Cnppd1 |
cyclin Pas1/PHO80 domain containing 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of CNPPD1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 9:76,633,475...76,640,164
Ensembl chr 9:76,633,477...76,640,188
|
|
G |
Cnpy2 |
canopy FGF signaling regulator 2 |
increases expression |
EXP |
Glafenine results in increased expression of CNPY2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:748,877...754,352
Ensembl chr 7:749,008...755,519
|
|
G |
Cnpy3 |
canopy FGF signaling regulator 3 |
increases expression |
EXP |
Glafenine results in increased expression of CNPY3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 9:14,233,478...14,247,847
Ensembl chr 9:14,233,428...14,247,831
|
|
G |
Coasy |
Coenzyme A synthase |
decreases expression |
EXP |
Glafenine results in decreased expression of COASY mRNA |
CTD |
PMID:24136188 |
|
NCBI chr10:86,014,566...86,018,849
Ensembl chr10:86,014,597...86,018,841
|
|
G |
Cog3 |
component of oligomeric golgi complex 3 |
increases expression |
EXP |
Glafenine results in increased expression of COG3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr15:51,020,808...51,071,288
Ensembl chr15:51,020,813...51,070,570
|
|
G |
Cog4 |
component of oligomeric golgi complex 4 |
decreases expression |
EXP |
Glafenine results in decreased expression of COG4 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr19:38,820,478...38,854,803
Ensembl chr19:38,820,501...38,854,796
|
|
G |
Col18a1 |
collagen type XVIII alpha 1 chain |
increases expression |
EXP |
Glafenine results in increased expression of COL18A1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr20:11,474,104...11,582,593
Ensembl chr20:11,474,104...11,582,593
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
increases expression |
EXP |
Glafenine results in increased expression of COL4A1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412
|
|
G |
Copa |
COPI coat complex subunit alpha |
increases expression |
EXP |
Glafenine results in increased expression of COPA mRNA |
CTD |
PMID:24136188 |
|
NCBI chr13:84,546,483...84,586,879
Ensembl chr13:84,545,943...84,586,874
|
|
G |
Cope |
COPI coat complex subunit epsilon |
increases expression |
EXP |
Glafenine results in increased expression of COPE mRNA |
CTD |
PMID:24136188 |
|
NCBI chr16:19,114,871...19,125,076
Ensembl chr16:19,114,871...19,128,907
|
|
G |
Copg1 |
COPI coat complex subunit gamma 1 |
increases expression |
EXP |
Glafenine results in increased expression of COPG1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:120,366,540...120,392,502
Ensembl chr 4:120,366,542...120,415,616
|
|
G |
Copg2 |
COPI coat complex subunit gamma 2 |
decreases expression |
EXP |
Glafenine results in decreased expression of COPG2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:59,366,086...59,501,591
Ensembl chr 4:59,366,086...59,501,618
|
|
G |
Copz1 |
COPI coat complex subunit zeta 1 |
increases expression |
EXP |
Glafenine results in increased expression of COPZ1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:134,409,523...134,435,661
Ensembl chr 7:134,409,799...134,435,662
|
|
G |
Copz2 |
COPI coat complex subunit zeta 2 |
increases expression |
EXP |
Glafenine results in increased expression of COPZ2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr10:81,832,441...81,845,514
Ensembl chr10:81,832,418...81,845,514
|
|
G |
Coq10a |
coenzyme Q10A |
decreases expression |
EXP |
Glafenine results in decreased expression of COQ10A mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:792,089...798,392
Ensembl chr 7:792,089...800,161
|
|
G |
Coq10b |
coenzyme Q10B |
increases expression |
EXP |
Glafenine results in increased expression of COQ10B mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 9:56,553,751...56,573,671
Ensembl chr 9:56,553,758...56,573,663
|
|
G |
Coq8a |
coenzyme Q8A |
decreases expression |
EXP |
Glafenine results in decreased expression of COQ8A mRNA |
CTD |
PMID:24136188 |
|
NCBI chr13:91,904,731...91,933,588
Ensembl chr13:91,904,739...91,931,431
|
|
G |
Cotl1 |
coactosin-like F-actin binding protein 1 |
increases expression |
EXP |
Glafenine results in increased expression of COTL1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr19:47,871,689...47,906,010
Ensembl chr19:47,871,694...47,911,689
|
|
G |
Cox5a |
cytochrome c oxidase subunit 5A |
decreases expression |
EXP |
Glafenine results in decreased expression of COX5A mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 8:57,922,374...57,933,781
Ensembl chr 8:57,922,290...57,933,781
|
|
G |
Cox5b |
cytochrome c oxidase subunit 5B |
increases expression |
EXP |
Glafenine results in increased expression of COX5B mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 9:38,921,980...38,923,806
Ensembl chr 9:38,921,967...38,925,052
|
|
G |
Cp |
ceruloplasmin |
increases expression |
EXP |
Glafenine results in increased expression of CP mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075
|
|
G |
Cpne3 |
copine 3 |
decreases expression |
EXP |
Glafenine results in decreased expression of CPNE3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:33,014,658...33,063,934
Ensembl chr 5:33,016,307...33,063,934
|
|
G |
Cpne8 |
copine 8 |
increases expression |
EXP |
Glafenine results in increased expression of CPNE8 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:121,615,293...121,789,507
Ensembl chr 7:121,615,294...121,790,377
|
|
G |
Cpped1 |
calcineurin-like phosphoesterase domain containing 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of CPPED1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr10:3,701,522...3,821,050
Ensembl chr10:3,701,459...3,821,054
|
|
G |
Cpq |
carboxypeptidase Q |
decreases expression |
EXP |
Glafenine results in decreased expression of PGCP mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:64,264,025...64,830,867
Ensembl chr 7:64,264,081...64,724,546
|
|
G |
Cps1 |
carbamoyl-phosphate synthase 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of CPS1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 9:68,614,153...68,737,037
Ensembl chr 9:68,614,153...68,737,033
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
decreases expression |
EXP |
Glafenine results in decreased expression of CPT2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
|
|
G |
Crat |
carnitine O-acetyltransferase |
decreases expression |
EXP |
Glafenine results in decreased expression of CRAT mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:13,675,684...13,689,282
Ensembl chr 3:13,675,684...13,689,255
|
|
G |
Crbn |
cereblon |
decreases expression |
EXP |
Glafenine results in decreased expression of CRBN mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:139,701,154...139,719,949
Ensembl chr 4:139,701,094...139,719,938
|
|
G |
Creb3l3 |
cAMP responsive element binding protein 3-like 3 |
decreases expression |
EXP |
Glafenine results in decreased expression of CREB3L3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:8,622,614...8,631,053
Ensembl chr 7:8,622,614...8,631,048
|
|
G |
Crebzf |
CREB/ATF bZIP transcription factor |
decreases expression |
EXP |
Glafenine results in decreased expression of CREBZF mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:144,416,864...144,423,540
Ensembl chr 1:144,417,446...144,428,553
|
|
G |
Creld2 |
cysteine-rich with EGF-like domains 2 |
increases expression |
EXP |
Glafenine results in increased expression of CRELD2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:119,909,626...119,916,556
Ensembl chr 7:119,909,633...119,916,543
|
|
G |
Crem |
cAMP responsive element modulator |
decreases expression |
EXP |
Glafenine results in decreased expression of CREM mRNA |
CTD |
PMID:24136188 |
|
NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989
|
|
G |
Crls1 |
cardiolipin synthase 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of CRLS1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:120,119,822...120,138,674
Ensembl chr 3:120,119,852...120,138,655
|
|
G |
Crot |
carnitine O-octanoyltransferase |
decreases expression |
EXP |
Glafenine results in decreased expression of CROT mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:25,068,270...25,133,111
Ensembl chr 4:25,080,587...25,133,109
|
|
G |
Crybg2 |
crystallin beta-gamma domain containing 2 |
decreases expression |
EXP |
Glafenine results in decreased expression of CRYBG2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:146,286,406...146,318,417
Ensembl chr 5:146,286,925...146,323,666
|
|
G |
Cryl1 |
crystallin, lambda 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of CRYL1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr15:31,427,011...31,545,997
Ensembl chr15:31,427,054...31,545,997
|
|
G |
Crym |
crystallin, mu |
decreases expression |
EXP |
Glafenine results in decreased expression of CRYM mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:174,560,423...174,575,660
Ensembl chr 1:174,560,416...174,575,633
|
|
G |
Cryz |
crystallin zeta |
decreases expression |
EXP |
Glafenine results in decreased expression of CRYZ mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:243,552,037...243,580,369
Ensembl chr 2:243,552,119...243,579,758
|
|
G |
Csf1 |
colony stimulating factor 1 |
increases expression |
EXP |
Glafenine results in increased expression of CSF1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Ctbs |
chitobiase |
decreases expression |
EXP |
Glafenine results in decreased expression of CTBS mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:235,340,520...235,355,091
Ensembl chr 2:235,340,547...235,355,091
|
|
G |
Cth |
cystathionine gamma-lyase |
decreases expression |
EXP |
Glafenine results in decreased expression of CTH mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234
|
|
G |
Ctnna1 |
catenin alpha 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of CTNNA1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr18:26,728,246...26,860,911
Ensembl chr18:26,728,485...26,860,910
|
|
G |
Ctps1 |
CTP synthase 1 |
increases expression |
EXP |
Glafenine results in increased expression of CTPS1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:134,125,022...134,154,155
Ensembl chr 5:134,125,025...134,154,180
|
|
G |
Ctsa |
cathepsin A |
decreases expression |
EXP |
Glafenine results in decreased expression of CTSA mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:153,569,106...153,574,983
Ensembl chr 3:153,568,381...153,576,215
|
|
G |
Ctsf |
cathepsin F |
decreases expression |
EXP |
Glafenine results in decreased expression of CTSF mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:202,152,777...202,158,525
Ensembl chr 1:202,152,728...202,158,525
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases expression |
EXP |
Glafenine results in increased expression of CXCL1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression |
EXP |
Glafenine results in decreased expression of CXCL12 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
decreases expression |
EXP |
Glafenine results in decreased expression of CXCL9 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435
|
|
G |
Cyb5r3 |
cytochrome b5 reductase 3 |
decreases expression |
EXP |
Glafenine results in decreased expression of CYB5R3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:114,306,686...114,324,247
Ensembl chr 7:114,306,685...114,324,298
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of CYP17A1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Glafenine results in decreased activity of CYP1A1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Glafenine results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp2a1 |
cytochrome P450, family 2, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of CYP2A1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:82,231,611...82,244,887
Ensembl chr 1:82,231,611...82,244,887
|
|
G |
Cyp2a2 |
cytochrome P450, family 2, subfamily a, polypeptide 2 |
decreases expression |
EXP |
Glafenine results in decreased expression of CYP2A2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:82,263,833...82,289,487
Ensembl chr 1:82,263,833...82,289,487
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of CYP2B1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases expression |
EXP |
Glafenine results in decreased expression of CYP2C11 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2d1 |
cytochrome P450, family 2, subfamily d, polypeptide 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of CYP2D1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:113,908,950...113,913,420
Ensembl chr 7:113,908,947...113,922,084
|
|
G |
Cyp2d2 |
cytochrome P450, family 2, subfamily d, polypeptide 2 |
decreases expression |
EXP |
Glafenine results in decreased expression of CYP2D2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:113,935,138...113,939,209
Ensembl chr 7:113,935,138...113,939,209
|
|
G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
decreases expression |
EXP |
Glafenine results in decreased expression of CYP2D3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:113,917,711...113,922,068
Ensembl chr 7:113,908,947...113,922,084
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases expression |
EXP |
Glafenine results in decreased expression of CYP2D4 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of CYP2E1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp2j3 |
cytochrome P450, family 2, subfamily j, polypeptide 3 |
decreases expression |
EXP |
Glafenine results in decreased expression of CYP2J3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:111,219,921...111,244,987
Ensembl chr 5:111,178,703...111,244,794
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
decreases expression |
EXP |
Glafenine results in decreased expression of CYP2J4 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794
|
|
G |
Cyp2t1 |
cytochrome P450, family 2, subfamily t, polypeptide 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of CYP2T1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 1:82,446,321...82,451,564
Ensembl chr 1:82,446,921...82,451,563
|
|
G |
Cyp39a1 |
cytochrome P450, family 39, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of CYP39A1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 9:17,230,455...17,306,775
Ensembl chr 9:17,230,455...17,306,775
|
|
G |
Cyp3a18 |
cytochrome P450, family 3, subfamily a, polypeptide 18 |
decreases expression |
EXP |
Glafenine results in decreased expression of CYP3A18 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr12:8,880,509...8,930,382
Ensembl chr12:8,880,528...8,930,381
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases expression |
EXP |
Glafenine results in decreased expression of CYP3A2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp4a1 |
cytochrome P450, family 4, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of CYP4A1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464
|
|
G |
Cyp4f1 |
cytochrome P450, family 4, subfamily f, polypeptide 1 |
decreases expression |
EXP |
Glafenine results in decreased expression of CYP4F1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:12,010,850...12,022,497
Ensembl chr 7:12,010,852...12,022,046
|
|
G |
Cyp4f4 |
cytochrome P450, family 4, subfamily f, polypeptide 4 |
decreases expression |
EXP |
Glafenine results in decreased expression of CYP4F4 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:11,717,208...11,733,507
Ensembl chr 7:11,717,208...11,733,506
|
|
G |
Dad1 |
defender against cell death 1 |
increases expression |
EXP |
Glafenine results in increased expression of DAD1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr15:27,677,286...27,697,120
Ensembl chr15:27,677,268...27,697,347
|
|
G |
Dao |
D-amino-acid oxidase |
decreases expression |
EXP |
Glafenine results in decreased expression of DAO mRNA |
CTD |
PMID:24136188 |
|
NCBI chr12:42,592,342...42,613,046
Ensembl chr12:42,592,343...42,612,741
|
|
G |
Dap |
death-associated protein |
increases expression |
EXP |
Glafenine results in increased expression of DAP mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 2:82,199,206...82,251,771
Ensembl chr 2:82,199,280...82,251,752
|
|
G |
Dcaf11 |
DDB1 and CUL4 associated factor 11 |
decreases expression |
EXP |
Glafenine results in decreased expression of DCAF11 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr15:29,046,744...29,057,450
Ensembl chr15:29,046,826...29,057,669
|
|
G |
Dcaf6 |
DDB1 and CUL4 associated factor 6 |
decreases expression |
EXP |
Glafenine results in decreased expression of DCAF6 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr13:77,626,257...77,727,645
Ensembl chr13:77,626,307...77,727,512
|
|
G |
Dcun1d4 |
defective in cullin neddylation 1 domain containing 4 |
decreases expression |
EXP |
Glafenine results in decreased expression of DCUN1D4 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr14:34,652,723...34,733,122
Ensembl chr14:34,652,723...34,733,207
|
|
G |
Dda1 |
DET1 and DDB1 associated 1 |
increases expression |
EXP |
Glafenine results in increased expression of DDA1 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr16:18,156,310...18,163,938
Ensembl chr16:18,156,386...18,163,937
|
|
G |
Ddc |
dopa decarboxylase |
decreases expression |
EXP |
Glafenine results in decreased expression of DDC mRNA |
CTD |
PMID:24136188 |
|
NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
Glafenine results in increased expression of DDIT3 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddost |
dolichyl-diphosphooligosaccharide--protein glycosyltransferase non-catalytic subunit |
increases expression |
EXP |
Glafenine results in increased expression of DDOST mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 5:150,522,297...150,529,413
Ensembl chr 5:150,522,242...150,529,413
|
|
G |
Ddx39a |
DExD-box helicase 39A |
increases expression |
EXP |
Glafenine results in increased expression of DDX39A mRNA |
CTD |
PMID:24136188 |
|
NCBI chr19:24,418,743...24,427,422
Ensembl chr19:24,418,114...24,426,954
|
|
G |
Ddx39b |
DExD-box helicase 39B |
increases expression |
EXP |
Glafenine results in increased expression of DDX39B mRNA |
CTD |
PMID:24136188 |
|
NCBI chr20:3,547,702...3,585,064
Ensembl chr20:3,572,056...3,584,996
|
|
G |
Ddx49 |
DEAD-box helicase 49 |
increases expression |
EXP |
Glafenine results in increased expression of DDX49 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr16:19,125,388...19,133,042
Ensembl chr16:19,125,384...19,133,616
|
|
G |
Decr2 |
2,4-dienoyl-CoA reductase 2 |
decreases expression |
EXP |
Glafenine results in decreased expression of DECR2 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr10:15,104,907...15,113,281
Ensembl chr10:15,002,926...15,118,479
|
|
G |
Dek |
DEK proto-oncogene |
decreases expression |
EXP |
Glafenine results in decreased expression of DEK mRNA |
CTD |
PMID:24136188 |
|
NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808
|
|
G |
Dennd6a |
DENN domain containing 6A |
decreases expression |
EXP |
Glafenine results in decreased expression of DENND6A mRNA |
CTD |
PMID:24136188 |
|
NCBI chr16:1,837,019...1,885,420
Ensembl chr16:1,837,059...1,885,420
|
|
G |
Depdc7 |
DEP domain containing 7 |
decreases expression |
EXP |
Glafenine results in decreased expression of DEPDC7 mRNA |
CTD |
PMID:24136188 |
|
NCBI chr 3:91,099,111...91,121,152
Ensembl chr 3:91,099,835...91,121,124
|
| |